<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6155776</article-id><article-id pub-id-type="doi">10.3390/molecules22020223</article-id><article-id pub-id-type="publisher-id">molecules-22-00223</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Synthesis of Novel Pyrazinamide Derivatives Based on 3-Chloropyrazine-2-carboxamide and Their Antimicrobial Evaluation </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jandourek</surname><given-names>Ondrej</given-names></name><xref ref-type="aff" rid="af1-molecules-22-00223">1</xref><xref rid="c1-molecules-22-00223" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Tauchman</surname><given-names>Marek</given-names></name><xref ref-type="aff" rid="af2-molecules-22-00223">2</xref></contrib><contrib contrib-type="author"><name><surname>Paterova</surname><given-names>Pavla</given-names></name><xref ref-type="aff" rid="af3-molecules-22-00223">3</xref></contrib><contrib contrib-type="author"><name><surname>Konecna</surname><given-names>Klara</given-names></name><xref ref-type="aff" rid="af1-molecules-22-00223">1</xref></contrib><contrib contrib-type="author"><name><surname>Navratilova</surname><given-names>Lucie</given-names></name><xref ref-type="aff" rid="af4-molecules-22-00223">4</xref></contrib><contrib contrib-type="author"><name><surname>Kubicek</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="af5-molecules-22-00223">5</xref></contrib><contrib contrib-type="author"><name><surname>Holas</surname><given-names>Ondrej</given-names></name><xref ref-type="aff" rid="af6-molecules-22-00223">6</xref></contrib><contrib contrib-type="author"><name><surname>Zitko</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="af2-molecules-22-00223">2</xref></contrib><contrib contrib-type="author"><name><surname>Dolezal</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="af2-molecules-22-00223">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Muñoz-Torrero</surname><given-names>Diego</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-22-00223"><label>1</label>Department of Biological and Medical Sciences, Teaching and Research Center of Charles University, Faculty of Pharmacy in Hradec Kralove, Charles University, Zborovska 2089, Hradec Kralove 50003, Czech Republic; <email>konecna@faf.cuni.cz</email></aff><aff id="af2-molecules-22-00223"><label>2</label>Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203/8, Hradec Kralove 50005, Czech Republic; <email>tauchmam@faf.cuni.cz</email> (M.T.); <email>zitkj3aa@faf.cuni.cz</email> (J.Z.); <email>dolezalm@faf.cuni.cz</email> (M.D.)</aff><aff id="af3-molecules-22-00223"><label>3</label>Department of Clinical Microbiology, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic; <email>pavla.paterova@fnhk.cz</email></aff><aff id="af4-molecules-22-00223"><label>4</label>Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203/8, Hradec Kralove 50005, Czech Republic; <email>navratl2@faf.cuni.cz</email></aff><aff id="af5-molecules-22-00223"><label>5</label>Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203/8, Hradec Kralove 50005, Czech Republic; <email>kubicek@faf.cuni.cz</email></aff><aff id="af6-molecules-22-00223"><label>6</label>Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203/8, Hradec Kralove 50005, Czech Republic; <email>holao3aa@faf.cuni.cz</email></aff><author-notes><corresp id="c1-molecules-22-00223"><label>*</label>Correspondence: <email>jando6aa@faf.cuni.cz</email>; Tel.: +420-495-067-366</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2017</year></pub-date><volume>22</volume><issue>2</issue><elocation-id>223</elocation-id><history><date date-type="received"><day>11</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Aminodehalogenation of 3-chloropyrazine-2-carboxamide with variously substituted benzylamines yielded a series of fifteen 3-benzylaminopyrazine-2-carboxamides. </plain></SENT>
<SENT sid="2" pm="."><plain>Four compounds possessed in vitro whole cell activity against Mycobacterium tuberculosis H37Rv that was at least equivalent to that of the standard pyrazinamide. </plain></SENT>
<SENT sid="3" pm="."><plain>MIC values ranged from 6 to 42 µM. </plain></SENT>
<SENT sid="4" pm="."><plain>The best MIC (6 µM) was displayed by 3-[(4-methylbenzyl)amino]pyrazine-2-carboxamide (8) that also showed low cytotoxicity in the HepG2 cell line (IC50 ≥ 250 µM). </plain></SENT>
<SENT sid="5" pm="."><plain>Only moderate activity against Enterococcus faecalis and Staphylococcus aureus was observed. </plain></SENT>
<SENT sid="6" pm="."><plain>No activity was detected against any of tested fungal strains. </plain></SENT>
<SENT sid="7" pm="."><plain>Molecular docking with mycobacterial enoyl-ACP reductase (InhA) was performed to investigate the possible target of the prepared compounds. </plain></SENT>
<SENT sid="8" pm="."><plain>Active compounds shared common binding interactions of known InhA inhibitors. </plain></SENT>
<SENT sid="9" pm="."><plain>Antimycobacterial activity of the title compounds was compared to the previously published benzylamino-substituted pyrazines with differing substitution on the pyrazine core (carbonitrile moiety). </plain></SENT>
<SENT sid="10" pm="."><plain>The title series possessed comparable activity and lower cytotoxicity than molecules containing a carbonitrile group on the pyrazine ring. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>tuberculosis</kwd><kwd>pyrazinamide</kwd><kwd>microwave-assisted</kwd><kwd>cytotoxicity</kwd><kwd>antibacterials</kwd><kwd>antifungals</kwd><kwd>benzylamines</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="sec1-molecules-22-00223"><title><text><SENT sid="11" pm="."><plain>1. </plain></SENT>
<SENT sid="12" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Tuberculosis (TB) still remains a global health problem despite the decreasing total incidence of new cases. </plain></SENT>
<SENT sid="14" pm="."><plain>It is the second leading cause of death in the group of infectious diseases [1]. </plain></SENT>
<SENT sid="15" pm="."><plain>It is mainly caused by Mycobacterium tuberculosis (M. tbc). </plain></SENT>
<SENT sid="16" pm="."><plain>An estimated 10.4 million people developed TB and 1.8 million people died from TB in 2015 [1]. </plain></SENT>
<SENT sid="17" pm="."><plain>Although huge progress was noted in diagnostics and treatment, a major problem has arisen with resistance of mycobacterial strains to current therapies. </plain></SENT>
<SENT sid="18" pm="."><plain>These multidrug-resistant (MDR-TB) or extensively drug-resistant (XDR-TB) strains are immense threat that is necessary to focus on. </plain></SENT>
<SENT sid="19" pm="."><plain>A partial headway was made with the discovery of bedaquiline, a novel drug active against resistant mycobacterial strains [2]. </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>The current common therapy for non-resistant TB is based on administering a cocktail of first-line antitubercular agents (rifampicin/rifabutin, isoniazid, ethambutol and pyrazinamide) within a period lasting from six to twelve months. </plain></SENT>
<SENT sid="21" pm="."><plain>The last mentioned drug—pyrazinamide (PZA)—is successfully used to shorten the time needed for treatment up to two thirds. </plain></SENT>
<SENT sid="22" pm="."><plain>It is characterized by its unique ability to kill dormant forms of mycobacteria [3]. </plain></SENT>
<SENT sid="23" pm="."><plain>PZA is endowed with multiple mechanisms of action based on its parent form or its metabolite pyrazinoic acid (POA). </plain></SENT>
<SENT sid="24" pm="."><plain>One of the first theories associated with the mechanism of action of PZA is based on active transport of PZA into the mycobacterial cell and its subsequent activation via nicotinamidase (pyrazinamidase; EC 3.5.1.19) to POA. </plain></SENT>
<SENT sid="25" pm="."><plain>Upon intracellular accumulation, POA acidifies the inner compartment of this cell causing a disruption of membrane potentials and a dysfunction of pH-sensitive enzymes [4]. </plain></SENT>
<SENT sid="26" pm="."><plain>This principle was disproved last year by Peterson et al. [5]. </plain></SENT>
<SENT sid="27" pm="."><plain>Both PZA and POA also inhibit the specific mycobacterial enzyme Fatty Acid Synthase I (FAS I; EC 2.3.1.85). </plain></SENT>
<SENT sid="28" pm="."><plain>Inhibition of FAS I leads to a depletion of mycolic acids and to the disruption of a mycobacterial cell wall function [6]. </plain></SENT>
<SENT sid="29" pm="."><plain>Further research indicated that POA also inhibits trans-translation. </plain></SENT>
<SENT sid="30" pm="."><plain>This process is also vital for cells’ survival and its blockade induces cellular death [7]. </plain></SENT>
<SENT sid="31" pm="."><plain>One of the latest studies revealed that PZA inhibits aspartate decarboxylase (PanD; EC 4.1.1.11). </plain></SENT>
<SENT sid="32" pm="."><plain>This enzyme is responsible for the conversion of L-aspartic acid to β-alanine, which is necessary for CoA synthesis. </plain></SENT>
<SENT sid="33" pm="."><plain>A blockade of this biochemical pathway usually leads to the energy depletion and to the inability to survive [8]. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>PZA itself evinces unique physicochemical and chemical properties and its small molecule is exceedingly suitable for modifications. </plain></SENT>
<SENT sid="35" pm="."><plain>Alkylamino substitution of the pyrazine ring in positions 5- and 6- is quite well known and often results in good antimycobacterial activities [9,10,11,12]. </plain></SENT>
<SENT sid="36" pm="."><plain>This work deals with benzylamino derivatives since compounds containing a benzylamino moiety were previously reported as anti-infective substances. N-Benzylpyrazine-2-carboxamides (i.e., containing a benzylamino moiety attached to the pyrazine nucleus via a carbonyl linker) were reported by Servusova et al. to show moderate antitubercular activities [13,14,15]. </plain></SENT>
<SENT sid="37" pm="."><plain>Benzylamino derivatives of pyrazine (with a benzylamino moiety attached directly to the pyrazine core) reported by Zitko et al. and Jandourek et al. showed moderate activities as well [16,17]. </plain></SENT>
<SENT sid="38" pm="."><plain>In contrast to the compounds proposed in this article, the previously reported benzylamino derivatives contained at least one carbonitrile moiety (see Figure 1). </plain></SENT>
</text></p><p><text><SENT sid="39" pm="."><plain>Such modifications did not lead to an improved antitubercular effect. </plain></SENT>
<SENT sid="40" pm="."><plain>These results confirmed the validity of our intention to prepare novel derivatives with different substituents to improve efficacy and safety. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>We have chosen the pyrazine ring without carbonitrile moieties (lower cytotoxicity), with a free carboxamide group (possibility of activation to POA) and a benzylamino substituent directly attached through its amino group to the pyrazine core. </plain></SENT>
<SENT sid="42" pm="."><plain>These compounds were investigated to establish whether this combination made on the basis of previous publications would demonstrate better biological properties. </plain></SENT>
</text></p><p><text><SENT sid="43" pm="."><plain>3-Chloropyrazine-2-carboxamide was allowed to react with variously substituted benzylamines by means of the nucleophilic substitution of chlorine. </plain></SENT>
<SENT sid="44" pm="."><plain>Some of the intended reactions were carried out using microwave-assisted synthesis, which can save time and used materials according to the literature. </plain></SENT>
<SENT sid="45" pm="."><plain>In addition, yields usually tend to be higher [18]. </plain></SENT>
<SENT sid="46" pm="."><plain>We have investigated the differences between conventional organic synthesis (conventional heating methods) and microwave-assisted reaction and a comparison is reported. </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>Additional biological assays (antimycobacterial, antibacterial, antifungal) were performed to establish the scope of activity of these novel pyrazinamide derivatives that were preliminarily published in electronic conference contributions [19,20]. </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>Finally, prepared compounds were docked into the active site of M. tuberculosis enoyl-ACP reductase (InhA; EC 1.3.1.9). </plain></SENT>
<SENT sid="49" pm="."><plain>InhA has been repeatedly evaluated as an effective antimycobacterial target. </plain></SENT>
<SENT sid="50" pm="."><plain>It is a crucial enzyme involved in the biosynthesis of long chain fatty acids. </plain></SENT>
<SENT sid="51" pm="."><plain>It is responsible for the reduction of the double bond between C2 and C3 of the enoyl intermediate linked to the acyl carrier protein (ACP). </plain></SENT>
<SENT sid="52" pm="."><plain>The inhibition of InhA leads to an insufficient synthesis of mycolic acids, which are essential for mycobacterial cell wall integrity [21]. </plain></SENT>
<SENT sid="53" pm="."><plain>A molecular modeling study has been performed to verify if InhA inhibition is a possible mechanism of action for the prepared derivatives due to their structural similarity to known InhA inhibitors such as triclosan or PT70. </plain></SENT>
<SENT sid="54" pm="."><plain>It is obvious that the requirement of two planar heteroaromatic or aromatic structural fragments connected with a linker, which is specifically represented by -NH-CH2- formation, is fulfilled. </plain></SENT>
<SENT sid="55" pm="."><plain>Another resemblance is actually expressed by a carbonyl part of carboxamide group serving as a hydrogen bond accepting moiety. </plain></SENT>
<SENT sid="56" pm="."><plain>These structural features are shared with typical InhA inhibitors [22]. </plain></SENT>
<SENT sid="57" pm="."><plain>Molecular targets of PZA/POA as discussed above were considered for docking simulations. </plain></SENT>
<SENT sid="58" pm="."><plain>However, there are limitations that make them inapplicable for our compounds. </plain></SENT>
<SENT sid="59" pm="."><plain>The complex of POA bound to the ribosomal protein S1 (involved in trans-translation process) was resolved (pdb: 4NNI). </plain></SENT>
<SENT sid="60" pm="."><plain>From this complex it is obvious that POA could be substituted in positions 5- and/or 6-, but not in position 3- [23]. </plain></SENT>
<SENT sid="61" pm="."><plain>The pyrazinamidase (PncA) active site cavity is quite small and from a model based on the X-ray determined structure of PncA (pdb: 3PL1), it is quite obvious that the only position for possible substitutions of PZA is position 6- of the pyrazine ring [24]. </plain></SENT>
<SENT sid="62" pm="."><plain>Substitution of position 3- by a large moiety (benzylamino in our case) would push the PZA core away from the position and orientation needed for an enzymatic conversion by PncA. </plain></SENT>
<SENT sid="63" pm="."><plain>The crystal structure of aspartate decarboxylase (PanD) was resolved (pdb: 2C45), but there are no complexes with bound PZA/POA. </plain></SENT>
<SENT sid="64" pm="."><plain>The binding site and interaction patterns for PZA/POA are therefore unknown. </plain></SENT>
<SENT sid="65" pm="."><plain>Simulations of PZA/POA binding to PanD by docking and docking followed by molecular dynamics simulation of the complex gave uncertain results [25]. </plain></SENT>
<SENT sid="66" pm="."><plain>The FAS I enzyme complex is very extensive so an X-ray resolved crystal structure of sufficient quality is not yet available [26]. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec id="sec2-molecules-22-00223"><title><text><SENT sid="67" pm="."><plain>2. </plain></SENT>
<SENT sid="68" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><sec id="sec2dot1-molecules-22-00223"><title><text><SENT sid="69" pm="."><plain>2.1. </plain></SENT>
<SENT sid="70" pm="."><plain>Chemistry </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>The starting compound 3-chloropyrazine-2-carboxamide was synthesized from 3-chloro-pyrazine-2-carbonitrile through a partial hydrolysis of the nitrile group under controlled conditions involving a specific pH and temperature [27]. </plain></SENT>
<SENT sid="72" pm="."><plain>This procedure was chosen on the basis of the higher yields obtained compared to the direct amidation of the pyrazine ring [27,28]. </plain></SENT>
</text></p><p><text><SENT sid="73" pm="."><plain>This initial compound then reacted with variously substituted benzylamines (see Scheme 1). </plain></SENT>
<SENT sid="74" pm="."><plain>Six final compounds 1–6 were prepared by conventional heating methods utilizing tetrahydrofuran (THF) as a solvent, triethylamine as a base and two equivalents of corresponding benzylamine. </plain></SENT>
<SENT sid="75" pm="."><plain>Reactions were stopped after 15 h and their progress was checked using TLC and the hexane−ethyl acetate (1:1) system as eluent. </plain></SENT>
<SENT sid="76" pm="."><plain>Products were purified by preparative flash chromatography and the final yields ranged between 24% and 50%. </plain></SENT>
<SENT sid="77" pm="."><plain>These low values prompted us to complete the series under microwave conditions. </plain></SENT>
<SENT sid="78" pm="."><plain>Thus compounds 7–15 were prepared successfully in a MW reactor using methanol as a solvent and pyridine as a base. </plain></SENT>
<SENT sid="79" pm="."><plain>Sealed thick-walled tubes were used as an over-pressurized system to reach a higher temperature (140 °C) than the standard boiling point of methanol. </plain></SENT>
<SENT sid="80" pm="."><plain>Time needed for a conversion was shortened from 15 h to 30 min. </plain></SENT>
<SENT sid="81" pm="."><plain>The final compounds were also purified using flash chromatography. </plain></SENT>
<SENT sid="82" pm="."><plain>Not surprisingly, the yields were 70% on average, and ranged from 26% to 80%. </plain></SENT>
<SENT sid="83" pm="."><plain>The lowest yield (26%) was observed for compound 15 that is substituted with a nitro group in the meta position. </plain></SENT>
<SENT sid="84" pm="."><plain>In general, it is hard to obtain higher yields with this kind of substitution as its electron withdrawing properties decrease the nucleophilicity of the benzylamino nitrogen. </plain></SENT>
<SENT sid="85" pm="."><plain>The difference between these two approaches can highlight the advantages of microwave-assisted reactions. </plain></SENT>
<SENT sid="86" pm="."><plain>The time needed to complete conversions was shortened ten times and the amount of solvents used was substantially minimized. </plain></SENT>
<SENT sid="87" pm="."><plain>The variance between yields was also significant. </plain></SENT>
<SENT sid="88" pm="."><plain>On the other hand, some limitations are emerging with this technology. </plain></SENT>
<SENT sid="89" pm="."><plain>It can be stated that not every base is usable for microwave-assisted reactions. </plain></SENT>
<SENT sid="90" pm="."><plain>Triethylamine, which acted as a base for conventional heating reactions, is inapplicable for MW in consideration of the fact that a molecule of TEA decomposes during the process. </plain></SENT>
<SENT sid="91" pm="."><plain>Byproducts (e.g., diethylamine) can react with starting compounds giving inadvertent side products [29,30]. </plain></SENT>
</text></p><p><text><SENT sid="92" pm="."><plain>The final products were characterized by 1H- and 13C-NMR spectra, IR spectroscopy, elemental analysis, and also by their melting points. </plain></SENT>
<SENT sid="93" pm="."><plain>The acquired analytical data were fully in accordance with proposed structures. </plain></SENT>
</text></p></sec><sec id="sec2dot2-molecules-22-00223"><title><text><SENT sid="94" pm="."><plain>2.2. </plain></SENT>
<SENT sid="95" pm="."><plain>Biological Assays </plain></SENT>
</text></title><sec id="sec2dot2dot1-molecules-22-00223"><title><text><SENT sid="96" pm="."><plain>2.2.1. </plain></SENT>
<SENT sid="97" pm="."><plain>Antimycobacterial Screening </plain></SENT>
</text></title><p><text><SENT sid="98" pm="."><plain>All of prepared compounds were screened for in vitro activity against Mycobacterium tuberculosis H37Rv, M. kansasii My 235/80 and M. avium 152/73. </plain></SENT>
<SENT sid="99" pm="."><plain>Experiments were carried out in a liquid broth with the pH value adjusted to 5.6. </plain></SENT>
<SENT sid="100" pm="."><plain>It is known that in vitro activity of PZA is strongly dependent on pH (MIC values ranging from units of µg/mL at pH 5.5 to hundreds of µg/mL in neutral conditions) [31,32,33,34]. </plain></SENT>
<SENT sid="101" pm="."><plain>Using neutral pH and high concentration is not appropriate for our compounds due to their limited solubility in the water-based testing medium. </plain></SENT>
<SENT sid="102" pm="."><plain>We were aware that acidic pH can negatively affect the growth of M. tbc. </plain></SENT>
<SENT sid="103" pm="."><plain>However, it was proved that M. tbc can be cultivated for 14–21 days of incubation under these conditions [35,36,37,38]. </plain></SENT>
<SENT sid="104" pm="."><plain>In our experiments, drug-free controls were included to validate the growth of mycobacteria under chosen acidic conditions. </plain></SENT>
<SENT sid="105" pm="."><plain>A microtitration plate assay was used to determine the activity and results were read using a resazurin dye-based methodology. </plain></SENT>
</text></p><p><text><SENT sid="106" pm="."><plain>The series contains compounds that showed activity against M. tuberculosis H37Rv. </plain></SENT>
<SENT sid="107" pm="."><plain>Such activity was detected for compounds 4, 8, 9 and 12, with MIC values in the range 1.56–12.5 µg/mL (resp. </plain></SENT>
<SENT sid="108" pm="."><plain>6–42 µM) as presented in Table 1. </plain></SENT>
<SENT sid="109" pm="."><plain>It cannot be stated that there is a dependence between the lipophilicity and the activity. </plain></SENT>
<SENT sid="110" pm="."><plain>The values of lipophilicity either for active or inactive compounds vary over a wide range (see Figure 2). </plain></SENT>
<SENT sid="111" pm="."><plain>Compounds 4 and 12 are substituted with a trifluoromethyl group, which is usually used fruitfully to prepare potentially active substances. </plain></SENT>
<SENT sid="112" pm="."><plain>On the other hand, these structures often show an undesirable higher cytotoxicity [16,39,40,41]. </plain></SENT>
<SENT sid="113" pm="."><plain>Cytotoxicity screening was performed for that reason. </plain></SENT>
<SENT sid="114" pm="."><plain>Contrarily, compounds 8 and 9 are substituted with less burdening groups and the activities demonstrated by them are more auspicious. </plain></SENT>
</text></p><p><text><SENT sid="115" pm="."><plain>Derivative 8 showed the best activity, which was close to the activity of the standard isoniazid (MIC = 3 µM) (see Table 1). </plain></SENT>
<SENT sid="116" pm="."><plain>Results were compared to the previously prepared corresponding 3-benzylamino-5-cyanopyrazine-2-carboxamides (Table 2, A), 3-benzylaminopyrazine-2,5-dicarbonitriles (Table 2, B) and 5-benzylamino-6-methylpyrazine-2,3-dicarbonitriles (Table 2, C) in order to compare the effect of cyano vs. carboxamide substitution. </plain></SENT>
</text></p><p><text><SENT sid="117" pm="."><plain>These results were mostly comparable. </plain></SENT>
<SENT sid="118" pm="."><plain>Nevertheless, there are some compounds that should be pointed out. </plain></SENT>
<SENT sid="119" pm="."><plain>Compound 4 (R = 3-CF3; MIC = 12.5 µg/mL) was more active than the matching substances 4-A (MIC = 25 µg/mL) or 4-B (MIC ≥ 100 µg/mL) and the activity of derivative 4-C (MIC = 12.5 µg/mL) was nearly the same [16,17]. </plain></SENT>
<SENT sid="120" pm="."><plain>Compound 9 (R = 4-NH2; MIC = 6.25 µg/mL) showed better activity than 9-A (MIC = 12.5 µg/mL), 9-B (MIC = 25 µg/mL) or 9-C (MIC = 25 µg/mL) [16,17]. </plain></SENT>
<SENT sid="121" pm="."><plain>Compound 1 (R = H; MIC ≥ 100 µg/mL) proved to be much less active than the corresponding dicarbonitriles 1-B (MIC = 12.5 µg/mL) and 1-C (MIC = 25 µg/mL). </plain></SENT>
<SENT sid="122" pm="."><plain>However, the corresponding cyanopyrazine-2-carboxamide (1-A; MIC ≥ 100 µg/mL) was also inactive [16,17]. </plain></SENT>
<SENT sid="123" pm="."><plain>In contrast, compound 8 (R = 4-CH3; MIC = 1.56 µg/mL) was certainly more active than the related compounds 8-B (MIC = 6.25 µg/mL), 8-A (MIC = 12.5 µg/mL) and 8-C (MIC = 25 µg/mL) [16,17]. </plain></SENT>
<SENT sid="124" pm="."><plain>It can be deduced that carbonitrile group on the pyrazine core is not necessary to obtain better activity and compounds without this modification are equally or more active against M. tuberculosis (see Table 2). </plain></SENT>
<SENT sid="125" pm="."><plain>Compounds 8 and 9 were afterwards tested for their antimycobacterial activity against four MDR-TB strains and one XDR-TB strain. </plain></SENT>
<SENT sid="126" pm="."><plain>Results of this screening are listed in Table 3. </plain></SENT>
<SENT sid="127" pm="."><plain>4-Amino derivative (MIC = 62.5 µM) showed better activity than 4-methyl derivative (MIC = 250 µM). </plain></SENT>
</text></p><p><text><SENT sid="128" pm="."><plain>Just one compound was effective against a mycobacterial strain other than M. tuberculosis with activity comparable to a standard. </plain></SENT>
<SENT sid="129" pm="."><plain>Specifically, derivative 4 showed activity against Mycobacterium kansasii (MIC = 25 µg/mL, resp. </plain></SENT>
<SENT sid="130" pm="."><plain>84 µM) whilst the MIC of isoniazid ranged between 1.56–12.5 µg/mL (resp. </plain></SENT>
<SENT sid="131" pm="."><plain>11–91 µM). </plain></SENT>
</text></p></sec><sec id="sec2dot2dot2-molecules-22-00223"><title><text><SENT sid="132" pm="."><plain>2.2.2. Mycobacterium smegmatis Screening </plain></SENT>
</text></title><p><text><SENT sid="133" pm="."><plain>Screening was performed again on the basis of adjusted microtitration plate assay with resazurin dye staining. </plain></SENT>
<SENT sid="134" pm="."><plain>This complementary test was completed in order to find any relationships between activities against typical slow growing mycobacterial strains and Mycobacterium smegmatis. </plain></SENT>
<SENT sid="135" pm="."><plain>The behavior of the last named microorganism is similar to that of other strains but it is not a human pathogen. </plain></SENT>
<SENT sid="136" pm="."><plain>Its generation time is also advantageous because it is disproportionally shorter. </plain></SENT>
<SENT sid="137" pm="."><plain>The results of this assay were dissimilar to the previous antimycobacterial screening. </plain></SENT>
<SENT sid="138" pm="."><plain>Poor activity was observed for three compounds, namely compounds 4, 5 and 9, as seen in Table 1. </plain></SENT>
<SENT sid="139" pm="."><plain>The value 250 µg/mL was not absolutely comparable to the used standards isoniazid (15.63 µg/mL), rifampicin (0.39 µg/mL) and ciprofloxacin (0.10 µg/mL). </plain></SENT>
<SENT sid="140" pm="."><plain>It is thus apparent that the prepared substances are active against M. tuberculosis and probably act through a pathway that is not common to both types of mycobacteria. </plain></SENT>
</text></p></sec><sec id="sec2dot2dot3-molecules-22-00223"><title><text><SENT sid="141" pm="."><plain>2.2.3. </plain></SENT>
<SENT sid="142" pm="."><plain>Antibacterial and Antifungal Screening </plain></SENT>
</text></title><p><text><SENT sid="143" pm="."><plain>All compounds were tested in vitro for their activity against eight common bacterial strains and eight fungal stems using standard methodology. </plain></SENT>
<SENT sid="144" pm="."><plain>Four of the fifteen synthesized substances exerted a moderate to low activity against Enterococcus faecalis, with values ranging between 62.5 µM and 125 µM (see Table 1). </plain></SENT>
<SENT sid="145" pm="."><plain>Compounds 4 and 5 were active against Staphylococcus aureus with a mean activity of 31.25 µM. </plain></SENT>
<SENT sid="146" pm="."><plain>All these results were insignificant in comparison with standards used in this screening. </plain></SENT>
<SENT sid="147" pm="."><plain>No antifungal activity was observed for any of the prepared substances. </plain></SENT>
</text></p></sec><sec id="sec2dot2dot4-molecules-22-00223"><title><text><SENT sid="148" pm="."><plain>2.2.4. </plain></SENT>
<SENT sid="149" pm="."><plain>Cytotoxicity Assays </plain></SENT>
</text></title><p><text><SENT sid="150" pm="."><plain>The most active compounds 4, 8, 9 and 12 were tested for their cytotoxic effects. </plain></SENT>
<SENT sid="151" pm="."><plain>Results of these experiments are presented as the inhibitory concentration required to decrease the viability of the cell population to 50% from the maximal viability (IC50) compared to 100% cell viability control. </plain></SENT>
<SENT sid="152" pm="."><plain>The cytotoxicity of the tested compounds was measured using the standard hepatic cell line HepG2. </plain></SENT>
</text></p><p><text><SENT sid="153" pm="."><plain>The used CellTiter 96® Aqueous One Solution Assay is based on a bioreduction of tetrazolium dye MTS by cells into a coloured formazan product, which is then determined colorimetrically. </plain></SENT>
<SENT sid="154" pm="."><plain>Reduction of this reagent is accomplished by NADPH or NADH produced in metabolically active cells. </plain></SENT>
<SENT sid="155" pm="."><plain>The quantity of formazan is therefore directly proportional to the number of living cells. </plain></SENT>
</text></p><p><text><SENT sid="156" pm="."><plain>Compounds can be divided into two groups according to their IC50 values as seen in Table 4. </plain></SENT>
<SENT sid="157" pm="."><plain>The first group is represented by substances 4 and 12 substituted with trifluoromethyl groups. </plain></SENT>
<SENT sid="158" pm="."><plain>The IC50 value in those cases is in the order of tens of µM, indicating a relatively high cytotoxicity. </plain></SENT>
<SENT sid="159" pm="."><plain>This course was expected according to the characteristics of the substituent that was stated above. </plain></SENT>
<SENT sid="160" pm="."><plain>It could be also connected with a higher lipophilicity causing intracellular accumulation. </plain></SENT>
<SENT sid="161" pm="."><plain>The second group of compounds (8, 9) showed encouraging results within the order of hundreds or thousands of µM. </plain></SENT>
</text></p><p><text><SENT sid="162" pm="."><plain>Actual IC50 values for these compounds could not be determined due to their low solubility at higher concentrations, but it is at least three orders better in comparison to compounds 4 and 12. </plain></SENT>
</text></p><p><text><SENT sid="163" pm="."><plain>The selectivity index (SI) was calculated for antimycobacterial activity (against M. tuberculosis) and was defined as a ratio between IC50 and MIC (µM). </plain></SENT>
<SENT sid="164" pm="."><plain>Values above 10 are considered to be safe values for a potential novel drug. </plain></SENT>
<SENT sid="165" pm="."><plain>This condition is met by compounds 8 and 9 (see Table 4). </plain></SENT>
</text></p></sec><sec id="sec2dot2dot5-molecules-22-00223"><title><text><SENT sid="166" pm="."><plain>2.2.5. </plain></SENT>
<SENT sid="167" pm="."><plain>Lipophilicity Determination </plain></SENT>
</text></title><p><text><SENT sid="168" pm="."><plain>Calculated lipophilicity parameters logP and ClogP were predicted using the ChemBioDraw Ultra 14 software (CambridgeSoft, Cambridge, MA, USA). </plain></SENT>
<SENT sid="169" pm="."><plain>These values were compared with logk, an experimentally measured lipophilicity parameter derived from retention times acquired by RP-HPLC. </plain></SENT>
<SENT sid="170" pm="."><plain>Theoretical (logP, ClogP) and experimental (logk) values were correlated to show a linear dependency, even though the values of logP and ClogP calculated by the ChemBioDraw algorithm did not reflect the influence of substituents’ positions on the aromatic ring (see Figure 3). </plain></SENT>
</text></p><p><text><SENT sid="171" pm="."><plain>Correlation of these parameters can be expressed by the following regression equations. </plain></SENT>
<SENT sid="172" pm="."><plain>Equation (1) shows the dependency of logP on logk. </plain></SENT>
<SENT sid="173" pm="."><plain>Compounds 7 and 14 were excluded from the calculations because their distinct values. </plain></SENT>
<SENT sid="174" pm="."><plain>It could be caused by the nature of the substituent group (a methoxy group). </plain></SENT>
<SENT sid="175" pm="."><plain>The logP algorithm underestimates the lipophilicity of methoxy-substituted derivatives, especially compound 14, according to the linear regression of logP on logk. </plain></SENT>
<SENT sid="176" pm="."><plain>The reason for the increased lipophilicity for compound 14 could be a formation of intramolecular H-bonds between the 2-OCH3 moiety (as an acceptor) and an amidic or amino hydrogen (donor). </plain></SENT>
<SENT sid="177" pm="."><plain>However, the conformational search by low mode molecular dynamics using AMBER10:EHT force field did not generate any pose with such intramolecular H-bond among conformers within a 7 kcal/mol energy window. </plain></SENT>
</text></p><p><text><SENT sid="178" pm="."><plain>Therefore, the discrepancy of logP prediction for 14 should be ascribed either to a systemic error in our measurements or to a suboptimal parametrization of -OCH3 fragment in the algorithm: logP = 0.397(±0.104) + 2.199(±0.263) logkR2 = 0.875, s = 0.194, F = 69.7, n = 12(1) </plain></SENT>
</text></p><p><text><SENT sid="179" pm="."><plain>Equation (2) expresses the dependency of ClogP on logk. </plain></SENT>
<SENT sid="180" pm="."><plain>This relationship is more predicative showing better regression parameters even for the methoxy derivatives 7 and 14: ClogP = 1.162(±0.074) + 2.726(±0.210) logkR2 = 0.934, s = 0.159, F = 168.6, n = 14(2) </plain></SENT>
</text></p><p><text><SENT sid="181" pm="."><plain>Compound 9 differs from the others in both parameters, which can be caused by the character of the substitution. </plain></SENT>
<SENT sid="182" pm="."><plain>Amino groups are usually easily ionized, which can result in distortion of the outcomes of the performed measurements. </plain></SENT>
</text></p></sec></sec><sec id="sec2dot3-molecules-22-00223"><title><text><SENT sid="183" pm="."><plain>2.3. </plain></SENT>
<SENT sid="184" pm="."><plain>Computational Studies—Docking </plain></SENT>
</text></title><p><text><SENT sid="185" pm="."><plain>The affinity calculation results show the important effect of a carboxamide group in the assessed compounds. </plain></SENT>
<SENT sid="186" pm="."><plain>The affinity towards InhA is high within a series containing compounds with substituents in the 3-position of the pyrazine core. </plain></SENT>
<SENT sid="187" pm="."><plain>Such an arrangement enables close proximity of the carbonyl group to Tyr 158 and NAD+ ribose and allows the substituent in the aforementioned 3- position to form additional less specific interactions with substrate binding group residues at the same time (see Figure 4). </plain></SENT>
</text></p><p><text><SENT sid="188" pm="."><plain>None of assessed compounds reached an affinity higher or equal to (3S)-1-cyclohexyl-N-(3,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide (−9.82 kcal/mol) that is the original 4TZK ligand. </plain></SENT>
<SENT sid="189" pm="."><plain>The best scored compounds 4 and 12 (affinity −8.47 kcal/mol resp. −8.49 kcal/mol, see Table 5) attain similar poses within the active site as most of the direct InhA inhibitors, forming a hydrogen bond network between Tyr 158, NAD+ ribose and the pyrazine core. </plain></SENT>
<SENT sid="190" pm="."><plain>The carboxamide moiety fulfils a similar role to the carbonyl moiety of the original ligand 4TZK or a phenolate of known inhibitors such as triclosan or PT70 (ring A) (see Figure 5). </plain></SENT>
<SENT sid="191" pm="."><plain>The hydrophobic benzyl part of discussed compounds exerts hydrophobic interactions with lipophilic residues of the substrate binding loop (Met 103, Pro 193, Met 199, Leu 207 and Ile 215, see Figure 6). </plain></SENT>
<SENT sid="192" pm="."><plain>An orientation of this benzyl moiety is in accordance with an orientation of hexyl chain of PT70 that is oriented in the hydrophobic entry tunnel, which normally hosts the long alkyl chain of mycolic acid intermediate (see Figure 5). </plain></SENT>
</text></p><p><text><SENT sid="193" pm="."><plain>The most efficient compound 8 did not achieve such a promising score compared to the standard ligand. </plain></SENT>
<SENT sid="194" pm="."><plain>This might happen because of a less hydrophobic substitution of the non-pyrazine molecule part that results in a less potent hydrophobic interactions with substrate binding loop hydrophobic residues. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="METHODS"><sec id="sec3-molecules-22-00223"><title><text><SENT sid="195" pm="."><plain>3. </plain></SENT>
<SENT sid="196" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec3dot1-molecules-22-00223"><title><text><SENT sid="197" pm="."><plain>3.1. </plain></SENT>
<SENT sid="198" pm="."><plain>General Methods </plain></SENT>
</text></title><p><text><SENT sid="199" pm="."><plain>All chemicals were of reagent or higher grade of purity. </plain></SENT>
<SENT sid="200" pm="."><plain>They were mainly purchased from Sigma-Aldrich or Fluka (Sigma-Aldrich, Co., Steinheim, Germany). </plain></SENT>
<SENT sid="201" pm="."><plain>Silica gel 60 F254 plates for thin layer chromatography (TLC) were provided by Merck KGaA (Darmstadt, Germany). </plain></SENT>
<SENT sid="202" pm="."><plain>Microwave assisted reactions were performed using a CEM Discover focused field microwave reactor equipped with an autosampler Explorer 24 (CEM Corporation, Matthews, NC, USA). </plain></SENT>
<SENT sid="203" pm="."><plain>Reaction progress was monitored with CEM’s Synergy™ software. </plain></SENT>
<SENT sid="204" pm="."><plain>All compounds were purified using preparative flash chromatography (CombiFlash® RF, Teledyne Isco, Inc., Lincoln, NE, USA). </plain></SENT>
<SENT sid="205" pm="."><plain>Silica gel (0.040–0.063 mm) was used as a stationary phase (Merck KGaA) and hexane (Lach-Ner, s.r.o., Neratovice, Czech Republic) together with ethyl acetate (Penta, Prague, Czech Republic) as a mobile phase in a gradient elution. </plain></SENT>
<SENT sid="206" pm="."><plain>NMR spectra were acquired at ambient temperature by Varian Mercury-VxBB 300 spectrometer (Varian Corp., Palo Alto, CA, USA) operating at 299.95 MHz for 1H and 75.43 MHz for 13C or Varian VNMR S500 spectrometer operating at 499.87 MHz for 1H, and 125.71 MHz for 13C. </plain></SENT>
<SENT sid="207" pm="."><plain>Chemical shifts were referenced in ppm (δ) and were indirectly related to TMS (tetramethylsilane) via the solvent signal (2.49 for 1H and 39.7 for 13C in DMSO-d6 or 7.28 for 1H and 77.0 for 13C in CDCl3). </plain></SENT>
<SENT sid="208" pm="."><plain>Infrared spectra were recorded using the Attenuated Total Reflectance (ATR) methodology on a Nicolet 6700 FT-IR spectrometer (Nicolet–Thermo Scientific, Waltham, MA, USA) on germanium crystals. </plain></SENT>
<SENT sid="209" pm="."><plain>Elemental analysis was performed on an EA 1110 CHNS Analyser (Fisons Instruments S. p. </plain></SENT>
<SENT sid="210" pm="."><plain>A., Carlo Erba, Milano, Italy) and values were given as percentages. </plain></SENT>
<SENT sid="211" pm="."><plain>Melting points were determined by a SMP3 Stuart Scientific apparatus (Bibby Sterling Ltd., Staffordshire, UK) in open capillary tubes and are uncorrected. </plain></SENT>
<SENT sid="212" pm="."><plain>Yields are expressed as percentages and refer to isolated products after all purification steps. </plain></SENT>
</text></p></sec><sec id="sec3dot2-molecules-22-00223"><title><text><SENT sid="213" pm="."><plain>3.2. </plain></SENT>
<SENT sid="214" pm="."><plain>General Synthetic Procedure </plain></SENT>
</text></title><p><text><SENT sid="215" pm="."><plain>The starting compound 3-chloropyrazine-2-carboxamide was prepared via partial hydrolysis of the nitrile group of 3-chloropyrazine-2-carbonitrile (Fluorochem, Co., Hadfield, Derbyshire, UK). </plain></SENT>
<SENT sid="216" pm="."><plain>A mixture of concentrated (30%) hydrogen peroxide (29 mL) and water (195 mL) was prepared and alkalinized with an 8% (w/v) solution of sodium hydroxide to obtain a solution with pH 9. </plain></SENT>
<SENT sid="217" pm="."><plain>The carbonitrile (104 mmol) was then added portionwise into the heated (50 °C) mixture over a period of 30 min. </plain></SENT>
<SENT sid="218" pm="."><plain>The whole mass was stirred for an additional 2.5 h at 55 °C while the pH was periodically monitored and alternatively adjusted to the value of 9 by adding a few drops of 8% NaOH solution. </plain></SENT>
<SENT sid="219" pm="."><plain>The reaction mixture was cooled in a fridge to initiate crystallization. </plain></SENT>
<SENT sid="220" pm="."><plain>The crude product was recrystallized from ethanol [27]. </plain></SENT>
<SENT sid="221" pm="."><plain>The yield of this reaction was approximately 80%. </plain></SENT>
</text></p><p><text><SENT sid="222" pm="."><plain>Compounds 1–6 were prepared according to conventional organic synthesis methods. </plain></SENT>
<SENT sid="223" pm="."><plain>3‑Chloropyrazine-2-carboxamide (1.27 mmol) was dissolved in THF (20 mL) in a round bottom flask and after that treated with two equivalents of the corresponding benzylamine and an equimolar amount of triethylamine. </plain></SENT>
<SENT sid="224" pm="."><plain>The reaction was conducted with continuous stirring and heating (70 °C) under reflux in an oil bath for 15 h. </plain></SENT>
<SENT sid="225" pm="."><plain>Compounds 7–15 were synthesised using a microwave reactor with a focused field. </plain></SENT>
<SENT sid="226" pm="."><plain>3-Chloropyrazine-2-carboxamide (1.27 mmol) was put into a thick-walled tube together with the corresponding benzylamine (2.54 mmol), pyridine (1.27 mmol), methanol (approx. </plain></SENT>
<SENT sid="227" pm="."><plain>5 mL) and a magnetic stir bar and then sealed with a special cap. </plain></SENT>
<SENT sid="228" pm="."><plain>The reaction parameters were set according to the previously published paper as follows—140 °C, 30 min, 200 W [29]. </plain></SENT>
<SENT sid="229" pm="."><plain>Reaction progress was checked by TLC (hexane:ethyl acetate—1:1). </plain></SENT>
<SENT sid="230" pm="."><plain>Regardless of the synthesis method used, all reaction mixtures were adsorbed on silica and subjected to preparative flash chromatography (hexane and ethyl acetate, gradient elution, detection wavelengths 260 nm and 280 nm). </plain></SENT>
<SENT sid="231" pm="."><plain>Products were recrystallized from ethanol or ethanol and water if necessary. </plain></SENT>
<SENT sid="232" pm="."><plain>All final substances were chemically characterized (1H-NMR, 13C-NMR, IR, melting point and elemental analysis). </plain></SENT>
</text></p></sec><sec id="sec3dot3-molecules-22-00223"><title><text><SENT sid="233" pm="."><plain>3.3. </plain></SENT>
<SENT sid="234" pm="."><plain>Analytical Data of the Prepared Compounds </plain></SENT>
</text></title><p><text><SENT sid="235" pm="."><plain>3-(Benzylamino)pyrazine-2-carboxamide (1). </plain></SENT>
<SENT sid="236" pm="."><plain>Yellow solid. </plain></SENT>
<SENT sid="237" pm="."><plain>Yield 35%; M.p. </plain></SENT>
<SENT sid="238" pm="."><plain>121.3–123.5 °C (125-126 °C in previously published work [42]); IR (ATR-Ge, cm−1): 3452 (-NH-), 3126 (-CONH2), 2869 (-CH2-), 1689 (-C=O), 1584, 1529, 1508, 1473, 1369, 1236, 1180 (arom.); 1H-NMR (500 MHz, DMSO) δ 9.14 (1H, t, J = 5.7 Hz, NH), 8.23 (1H, d, J = 2.4 Hz, H6), 8.18 (1H, bs, NH2), 7.79 (1H, d, J = 2,4 Hz, H5), 7.70 (1H, bs, NH2), 7.33−7.28 (4H, m, H2′, H3′, H5′, H6′), 7.25−7.20 (1H, m, H4′), 4.63 (2H, d, J = 5.7 Hz, CH2). 13C-NMR (125 MHz, DMSO) δ 169.0, 154.3, 146.5, 139.7, 130.2, 128.6, 127.4, 127.0, 126.7, 43.5. </plain></SENT>
<SENT sid="239" pm="."><plain>Elemental analysis found: C, 62.88%; H, 5.50%; N, 24.16%. </plain></SENT>
<SENT sid="240" pm="."><plain>Calculated for C12H12N4O (MW 228.25): C, 63.15%; H, 5.30%; N, 24.55%. </plain></SENT>
</text></p><p><text><SENT sid="241" pm="."><plain>3-[(3-Chlorobenzyl)amino]pyrazine-2-carboxamide (2). </plain></SENT>
<SENT sid="242" pm="."><plain>Dark yellow solid. </plain></SENT>
<SENT sid="243" pm="."><plain>Yield 32%; M.p. </plain></SENT>
<SENT sid="244" pm="."><plain>146.1–148.9 °C; IR (ATR-Ge, cm−1): 3435 (-NH-), 3196 (-CONH2), 2926 (-CH2-), 1666 (-C=O), 1578, 1534, 1511, 1408, 1338, 1262, 1231, 1189 (arom.); 1H-NMR (500 MHz, DMSO) δ 9.17 (1H, t, J = 6.0 Hz, NH), 8.22 (1H, d, J = 2.4 Hz, H6), 8.18 (1H, bs, NH2), 7.79 (1H, d, J = 2.4 Hz, H5), 7.71 (1H, bs, NH2), 7.39–7.23 (4H, m, H2′, H4′, H5′, H6′), 4.65 (2H, d, J = 6.0 Hz, CH2). 13C-NMR (125 MHz, DMSO) δ 168.9, 154.2, 146.5, 142.6, 133.2, 130.5, 130.4, 127.1, 126.9, 126.9, 126.0, 43.0. </plain></SENT>
<SENT sid="245" pm="."><plain>Elemental analysis found: C, 55.18%; H, 4.51%; N, 20.94%. </plain></SENT>
<SENT sid="246" pm="."><plain>Calculated for C12H11ClN4O (MW 262.69): C, 54.87%; H, 4.22%; N, 21.33%. </plain></SENT>
</text></p><p><text><SENT sid="247" pm="."><plain>3-[(3,4-Dichlorobenzyl)amino]pyrazine-2-carboxamide (3). </plain></SENT>
<SENT sid="248" pm="."><plain>Yellow solid. </plain></SENT>
<SENT sid="249" pm="."><plain>Yield 24%; M.p. </plain></SENT>
<SENT sid="250" pm="."><plain>169.5–172.1 °C; IR (ATR-Ge, cm−1): 3472 (-NH-), 3174 (-CONH2), 2924 (-CH2-), 1677 (-C=O), 1576, 1529, 1500, 1465, 1416, 1338, 1233, 1187 (arom.); 1H-NMR (300 MHz, DMSO) δ 9.19 (1H, t, J = 6.2 Hz, NH), 8.24–8.20 (1H, m, H6), 8.18 (1H, bs, NH2), 7.82–7.79 (1H, m, H5), 7.72 (1H, bs, NH2), 7.58–7.53 (1H, m, H5′), 7.53 (1H, d, J = 1.7 Hz, H6′), 4.64 (2H, d, J = 6.2 Hz, CH2). 13C-NMR (75 MHz, DMSO) δ 168.8, 154.1, 146.4, 141.4, 131.0, 130.7, 130.6, 129.3, 129.3, 127.7, 127.0, 42.5. </plain></SENT>
<SENT sid="251" pm="."><plain>Elemental analysis found: C, 49.09%; H, 3.76%; N, 18.69%. </plain></SENT>
<SENT sid="252" pm="."><plain>Calculated for C12H10Cl2N4O (MW 298.14): C, 48.86%; H, 3.39%; N, 18.86%. </plain></SENT>
</text></p><p><text><SENT sid="253" pm="."><plain>3-[(3-Trifluoromethylbenzyl)amino]pyrazine-2-carboxamide (4). </plain></SENT>
<SENT sid="254" pm="."><plain>Dark yellow solid. </plain></SENT>
<SENT sid="255" pm="."><plain>Yield 31%; M.p. </plain></SENT>
<SENT sid="256" pm="."><plain>98.1–100.3 °C; IR (ATR-Ge, cm−1): 3468 (-NH-), 3201 (-CONH2), 2937 (-CH2-), 1674 (-C=O), 1581, 1530, 1507, 1453, 1416, 1236, 1185, 1164 (arom.), 1331 (-CF3); 1H-NMR (500 MHz, DMSO) δ 9.23 (1H, t, J = 6.1 Hz, NH), 8.22 (1H, d, J = 2.2 Hz, H6), 8.19 (1H, bs, NH2), 7.80 (1H, d, J = 2.2 Hz, H5), 7.72 (1H, bs, NH2), 7.66 (1H, s, H2′), 7.64–7.50 (3H, m, H4′, H5′, H6′), 4.74 (2H, d, J = 6.1 Hz, CH2). 13C-NMR (125 MHz, DMSO) δ 168.9, 154.2, 146.4, 141.6, 131.4, 130.5, 129.6, 129.2 (q, J = 31.3 Hz), 127.0, 124.4 (q, J = 272.0 Hz), 123.8 (q, J = 3.9 Hz), 123.7 (q, J = 3.9 Hz), 43.1. </plain></SENT>
<SENT sid="257" pm="."><plain>Elemental analysis found: C, 52.48%; H, 3.40%; N, 18.76%. </plain></SENT>
<SENT sid="258" pm="."><plain>Calculated for C13H11F3N4O (MW 297.14): C, 52.71%; H, 3.74%; N, 18.91%. </plain></SENT>
</text></p><p><text><SENT sid="259" pm="."><plain>3-[(4-Chlorobenzyl)amino]pyrazine-2-carboxamide (5). </plain></SENT>
<SENT sid="260" pm="."><plain>Yellow solid. </plain></SENT>
<SENT sid="261" pm="."><plain>Yield 59%; M.p. </plain></SENT>
<SENT sid="262" pm="."><plain>141.0–142.0 °C; IR (ATR-Ge, cm−1): 3408 (-NH-), 3290 (-CONH2), 2930 (-CH2-), 1682 (-C=O), 1589, 1530, 1510, 1468, 1413, 1339, 1232, 1188 (arom.); 1H-NMR (500 MHz, DMSO) δ 9.17 (1H, bs, NH), 8.23–8.20 (1H, m, H6), 8.18 (1H, bs, NH2), 7.81–7.77 (1H, m, H5), 7.71 (1H, bs, NH2), 7.38–7.30 (4H, m, H2′, H3′, H5′, H6′), 4.63 (2H, d, J = 5.9 Hz, CH2). 13C-NMR (125 MHz, DMSO) δ 168.9, 154.2, 146.5, 139.0, 131.4, 130.4, 129.2, 128.5, 126.9, 42.8. </plain></SENT>
<SENT sid="263" pm="."><plain>Elemental analysis found: C, 55.08%; H, 4.64%; N, 21.58%. </plain></SENT>
<SENT sid="264" pm="."><plain>Calculated for C12H11ClN4O (MW 262.69): C, 54.87%; H, 4.22%; N, 21.33%. </plain></SENT>
</text></p><p><text><SENT sid="265" pm="."><plain>3-[(2-Methylbenzyl)amino]pyrazine-2-carboxamide (6). </plain></SENT>
<SENT sid="266" pm="."><plain>Yellow solid. </plain></SENT>
<SENT sid="267" pm="."><plain>Yield 38%; M.p. </plain></SENT>
<SENT sid="268" pm="."><plain>148.3–150.5 °C; IR (ATR-Ge, cm−1): 3435 (-NH-), 3201 (-CONH2), 2925 (-CH2-), 1665 (-C=O), 1575, 1536, 1512, 1465, 1411, 1339, 1229, 1192 (arom.); 1H-NMR (500 MHz, DMSO) δ 9.03 (1H, bs, NH), 8.24 (1H, s, H6), 8.19 (1H, bs, NH2), 7.79 (1H, s, H5), 7.70 (1H, bs, NH2), 7.27–7.06 (4H, m, H3′, H4′, H5′, H6′), 4.60 (2H, d, J = 4.9 Hz, CH2), 2.30 (3H, s, CH3). 13C-NMR (125 MHz, DMSO) δ 169.0, 154.4, 146.4, 137.2, 135.9, 130.3, 130.2, 127.5, 127.2, 126.7, 126.1, 41.8, 18.8. </plain></SENT>
<SENT sid="269" pm="."><plain>Elemental analysis found: C, 64.28%; H, 6.07%; N, 22.90%. </plain></SENT>
<SENT sid="270" pm="."><plain>Calculated for C13H14N4O (MW 242.28): C, 64.45%; H, 5.82%; N, 23.13%. </plain></SENT>
</text></p><p><text><SENT sid="271" pm="."><plain>3-[(4-Methoxybenzyl)amino]pyrazine-2-carboxamide (7). </plain></SENT>
<SENT sid="272" pm="."><plain>Yellow solid. </plain></SENT>
<SENT sid="273" pm="."><plain>Yield 73%; M.p. </plain></SENT>
<SENT sid="274" pm="."><plain>148.5–151.3 °C; IR (ATR-Ge, cm−1): 3464 (-NH-), 3126 (-CONH2), 2952 (-OCH3), 2910 (-CH2-), 1690 (-C=O), 1612, 1582, 1530, 1509, 1469, 1413, 1245, 1173 (arom.); 1H-NMR (300 MHz, DMSO) δ 9.04 (1H, t, J = 5.7 Hz, NH), 8.24 (1H, d, J = 2,4 Hz, H6), 8.15 (1H, bs, NH2), 7.78 (1H, d, J = 2,5 Hz, H5), 7.67 (1H, bs, NH2), 7.28–7.23 (2H, m, H2′,H6′), 6.90–6.85 (2H, m, H3′, H5′), 4.55 (2H, d, J = 5.7 Hz, CH2), 3.71 (3H, s, OCH3). 13C-NMR (75 MHz, DMSO) δ 168.88, 158.44, 154.25, 146.52, 131.45, 130.10, 128.82, 126.65, 114.00, 55.20, 43.05. </plain></SENT>
<SENT sid="275" pm="."><plain>Elemental analysis found: C, 60.74%; H, 5.93%; N, 21.71%. </plain></SENT>
<SENT sid="276" pm="."><plain>Calculated for C13H14N4O2 (MW 258.25): C, 60.45%; H, 5.46%; N, 21.69%. </plain></SENT>
</text></p><p><text><SENT sid="277" pm="."><plain>3-[(4-Methylbenzyl)amino]pyrazine-2-carboxamide (8). </plain></SENT>
<SENT sid="278" pm="."><plain>Yellow solid. </plain></SENT>
<SENT sid="279" pm="."><plain>Yield 72%; M.p. </plain></SENT>
<SENT sid="280" pm="."><plain>145.0–146.9 °C; IR (ATR-Ge, cm−1): 3427 (-NH-), 3195 (-CONH2), 2926 (-CH2-), 1669 (-C=O), 1579, 1531, 1503, 1419, 1333, 1232, 1188 (arom.); 1H-NMR (300 MHz, DMSO) δ 9.08 (1H, t, J = 6.0 Hz, NH), 8.23 (1H, d, J = 2.4 Hz, H6), 8.16 (1H, s, NH2), 7.78 (1H, d, J = 2.5 Hz, H5), 7.68 (1H, s, NH2), 7.21–7.10 (4H, dd, H2′, H3′, H5′, H6′), 4.58 (2H, d, J = 5.8 Hz, CH2), 2.25 (3H, s, CH3). 13C-NMR (75 MHz, DMSO) δ 168.95, 154.30, 146.52, 136.54, 136.08, 130.15, 129.13, 127.40, 126.68, 43.32, 20.84. </plain></SENT>
<SENT sid="281" pm="."><plain>Elemental analysis found: C, 64.98%; H, 6.32%; N, 22.84%. </plain></SENT>
<SENT sid="282" pm="."><plain>Calculated for C13H14N4O (MW 242.28): C, 64.45%; H, 5.82%; N, 23.13%. </plain></SENT>
</text></p><p><text><SENT sid="283" pm="."><plain>3-[(4-Aminobenzyl)amino]pyrazine-2-carboxamide (9). </plain></SENT>
<SENT sid="284" pm="."><plain>Ochre solid. </plain></SENT>
<SENT sid="285" pm="."><plain>Yield 46%; M.p. </plain></SENT>
<SENT sid="286" pm="."><plain>140.8–142.3 °C; IR (ATR-Ge, cm−1): 3426 (-NH-), 3324 (-NH2), 3194 (-CONH2), 1670 (-C=O), 1614, 1578, 1514, 1464, 1413, 1231, 1191 (arom.); 1H-NMR (300 MHz, DMSO) δ 8.89 (1H, t, J = 5.5 Hz, NH), 8.24 (1H, d, J = 2.3 Hz, H6), 8.13 (1H, s, NH2), 7.76 (1H, d, J = 2.3 Hz, H5), 7.65 (1H, s, NH2), 7.03–6.97 (2H, m, H2′, H6′), 6.54–6.48 (2H, m, H3′, H5′), 4.97 (2H, s, NH2′), 4.41 (2H, d, J = 5.5 Hz, CH2). 13C-NMR (75 MHz, DMSO) δ 168.97, 154.24, 147.91, 146.58, 129.87, 128.63, 126.49, 126.04, 114.03, 43.56. </plain></SENT>
<SENT sid="287" pm="."><plain>Elemental analysis found: C, 58.78%; H, 5.79%; N, 29.04%. </plain></SENT>
<SENT sid="288" pm="."><plain>Calculated for C12H13N5O (MW 243.26): C, 59.25%; H, 5.39%; N, 28.79%. </plain></SENT>
</text></p><p><text><SENT sid="289" pm="."><plain>3-[(2-Chlorobenzyl)amino]pyrazine-2-carboxamide (10). </plain></SENT>
<SENT sid="290" pm="."><plain>Ochre solid. </plain></SENT>
<SENT sid="291" pm="."><plain>Yield 80%; M.p. </plain></SENT>
<SENT sid="292" pm="."><plain>182.4–184.3 °C; IR (ATR-Ge, cm−1): 3456 (-NH-), 3291 (-CONH2), 2921 (-CH2-), 1661 (-C=O), 1583, 1569, 1509, 1471, 1409, 1231, 1187 (arom.); 1H-NMR (300 MHz, DMSO) δ 9.19 (1H, t, J = 6.1 Hz, NH), 8.22 (1H, d, J = 2.4 Hz, H6), 8.19 (1H, s, NH2), 7.81 (1H, d, J = 2.3 Hz, H5), 7.71 (1H, s, NH2), 7.47–7.41 (1H, m, H5′), 7.36–7.22 (3H, m, H2′, H3′, H4′), 4.71 (2H, d, J = 6.1 Hz, CH2). 13C-NMR (75 MHz, DMSO) δ 168.86, 154.17, 146.44, 136.69, 132.43, 130.51, 129.40, 128.90, 128.77, 127.37, 126.96, 41.64. </plain></SENT>
<SENT sid="293" pm="."><plain>Elemental analysis found: C, 55.11%; H, 4.65%; N, 21.02%. </plain></SENT>
<SENT sid="294" pm="."><plain>Calculated for C12H11ClN4O (MW 262.69): C, 54.87%; H, 4.22%; N, 21.33%. </plain></SENT>
</text></p><p><text><SENT sid="295" pm="."><plain>3-[(2-Fluorobenzyl)amino]pyrazine-2-carboxamide (11). </plain></SENT>
<SENT sid="296" pm="."><plain>Dark yellow solid. </plain></SENT>
<SENT sid="297" pm="."><plain>Yield 66%; M.p. </plain></SENT>
<SENT sid="298" pm="."><plain>171.3–174.3 °C; IR (ATR-Ge, cm−1): 3446 (-NH-), 3277 (-CONH2), 2921 (-CH2-), 1666 (-C=O), 1572, 1534, 1514, 1486, 1420, 1225, 1190 (arom.); 1H-NMR (300 MHz, DMSO) δ 9.13 (1H, t, J = 5.9 Hz, NH), 8.23 (1H, d, J = 1.8 Hz, H6), 8.18 (1H, s, NH2), 7.80 (1H, d, J = 1.7 Hz, H5), 7.71 (1H, s, NH2), 7.40–7.08 (4H, m, H2′, H3′, H4′, H5′), 4.70 (2H, d, J = 6.0 Hz, CH2). 13C-NMR (75 MHz, DMSO) δ 168.88, 162.12, 158.88, 154.21, 146.45, 130.44, 129.57–128.54 (m), 126.91, 126.36 (d, J = 14.7 Hz), 124.53 (d, J = 3.4 Hz), 115.33 (d, J = 21.0 Hz), 37.62 (d, J = 4.4 Hz). </plain></SENT>
<SENT sid="299" pm="."><plain>Elemental analysis found: C, 58.73%; H, 4.19%; N, 22.32%. </plain></SENT>
<SENT sid="300" pm="."><plain>Calculated for C12H11FN4O (MW 246.24): C, 58.53%; H, 4.50%; N, 22.75%. </plain></SENT>
</text></p><p><text><SENT sid="301" pm="."><plain>3-[(4-Trifluoromethylbenzyl)amino]pyrazine-2-carboxamide (12). </plain></SENT>
<SENT sid="302" pm="."><plain>Yellow solid. </plain></SENT>
<SENT sid="303" pm="."><plain>Yield 46%; M.p. </plain></SENT>
<SENT sid="304" pm="."><plain>136.8–138.3 °C; IR (ATR-Ge, cm−1): 3423 (-NH-), 3257 (-CONH2), 1678 (-C=O), 1584, 1532, 1510, 1414, 1231, 1189 (arom.), 1322 (-CF3); 1H-NMR (300 MHz, DMSO) δ 9.25 (1H, t, J = 6.1 Hz, NH), 8.20 (1H, d, J = 2.4 Hz, H6), 8.18 (1H, s, NH2), 7.80 (1H, d, J = 2.4 Hz, H5), 7.74 (1H, s, NH2), 7.65 (2H, d, J = 8.0 Hz, H2′, H6′), 7.51 (2H, d, J = 7.9 Hz, H3′. </plain></SENT>
<SENT sid="305" pm="."><plain>H5′), 4.74 (2H, d, J = 6.1 Hz, CH2). 13C-NMR (75 MHz, DMSO) δ 168.91, 154.23, 146.44, 145.00 (d, J = 1.7 Hz), 130.52, 127.86, 127.34, 126.97, 126.35, 125.38 (q, J = 3.8 Hz), 122.74, 43.14, 40.53. </plain></SENT>
<SENT sid="306" pm="."><plain>Elemental analysis found: C, 52.83%; H, 3.87%; N, 18.73%. </plain></SENT>
<SENT sid="307" pm="."><plain>Calculated for C13H11F3N4O (MW 296.25): C, 52.71%; H, 3.74%; N, 18.91%. </plain></SENT>
</text></p><p><text><SENT sid="308" pm="."><plain>3-[(2-Trifluoromethylbenzyl)amino]pyrazine-2-carboxamide (13). </plain></SENT>
<SENT sid="309" pm="."><plain>Light yellow solid. </plain></SENT>
<SENT sid="310" pm="."><plain>Yield 55%; M.p. </plain></SENT>
<SENT sid="311" pm="."><plain>173.7–175.3 °C; IR (ATR-Ge, cm−1): 3456 (-NH-), 3254 (-CONH2), 1672 (-C=O), 1586, 1578, 1516, 1414, 1232, 1189 (arom.), 1339 (-CF3); 1H-NMR (300 MHz, DMSO) δ 9.22 (1H, t, J = 5.9 Hz, NH), 8.21 (1H, d, J = 1.8 Hz, H6), 8.20 (1H, s, NH2), 7.82 (1H, d, J = 2.1 Hz, H5), 7.81 (1H, s, NH2), 7.72 (1H, J = 8.5 Hz, H5′), 7.64–7.39 (3H, m, H2′, H3′, H4′), 4.85 (2H, d, J = 5.9 Hz, CH2). 13C-NMR (75 MHz, DMSO) δ 168.88, 154.13, 146.46, 138.07 (d, J = 1.9 Hz), 132.90, 130.64, 128.78, 127.53, 127.04, 126.88–125.82 (m), 122.94, 40.36, 40.31. </plain></SENT>
<SENT sid="312" pm="."><plain>Elemental analysis found: C, 53.05%; H, 3.86%; N, 18.74%. </plain></SENT>
<SENT sid="313" pm="."><plain>Calculated for C13H11F3N4O (MW 296.25): C, 52.71%; H, 3.74%; N, 18.91%. </plain></SENT>
</text></p><p><text><SENT sid="314" pm="."><plain>3-[(2,4-Dimethoxybenzyl)amino]pyrazine-2-carboxamide (14). </plain></SENT>
<SENT sid="315" pm="."><plain>Yellow solid. </plain></SENT>
<SENT sid="316" pm="."><plain>Yield 66%; M.p. </plain></SENT>
<SENT sid="317" pm="."><plain>147.9–149.6 °C; IR (ATR-Ge, cm−1): 3403 (-NH-), 3215 (-CONH2), 2951 (-OCH3), 2832 (-CH2-), 1677 (-C=O), 1650, 1617, 1578, 1535, 1506, 1468, 1427, 1250, 1190, 1158 (arom.); 1H-NMR (300 MHz, DMSO) δ 9.00 (1H, t, J = 5.7 Hz, NH), 8.23 (1H, d, J = 2.4 Hz, H6), 8.12 (1H, s, NH2), 7.75 (1H, d, J = 2.4 Hz, H5), 7.64 (1H, s, NH2), 7.11 (1H, d, J = 8.3 Hz, H2′), 6.57 (1H, d, J = 2.4 Hz, H3′), 6.44 (1H, dd, J = 8.3, 2.4 Hz, H5′), 4.49 (2H, d, J = 5.7 Hz, CH2), 3.80 (3H, s, OCH3), 3.72 (3H, s, OCH3). 13C-NMR (75 MHz, DMSO) δ 189.90, 168.94, 160.05, 158.31, 154.34, 146.53, 129.85, 129.28, 126.64, 119.01, 104.51, 98.66, 55.61, 55.35. </plain></SENT>
<SENT sid="318" pm="."><plain>Elemental analysis found: C, 58.52%; H, 6.08%; N, 19.38%. </plain></SENT>
<SENT sid="319" pm="."><plain>Calculated for C14H16N4O3 (MW 288.30): C, 58.32%; H, 5.59%; N, 19.43%. </plain></SENT>
</text></p><p><text><SENT sid="320" pm="."><plain>3-[(3-Nitrobenzyl)amino]pyrazine-2-carboxamide (15). </plain></SENT>
<SENT sid="321" pm="."><plain>Light brown solid. </plain></SENT>
<SENT sid="322" pm="."><plain>Yield 26%; M.p. </plain></SENT>
<SENT sid="323" pm="."><plain>165.6–168.3 °C; IR (ATR-Ge, cm−1): 3423 (-NH-), 3193 (-CONH2), 2923 (-CH2-), 1668 (-C=O), 1578, 1511, 1461, 1412, 1232, 1185 (arom.), 1522, 1347 (-NO2); 1H- NMR (300 MHz, DMSO) δ 9.28 (1H, t, J = 6.2 Hz, NH), 8.21 (1H, d, J = 2.5 Hz, H6), 8.19 (1H, s, NH2), 8.16 (1H, t, J = 2.0 Hz, H6′), 8.07 (1H, m, H4′), 7.81 (1H, d, J = 2.4 Hz, H5), 7.79 (1H, s, NH2), 7.77–7.70 (1H, m, H2′), 7.59 (1H, t, J = 7.9 Hz, H3′), 4.78 (2H, d, J = 6.2 Hz, CH2). 13C-NMR (75 MHz, DMSO) δ 168.82, 154.10, 147.99, 146.39, 142.62, 134.10, 130.64, 130.00, 127.05, 121.88, 121.84, 42.90. </plain></SENT>
<SENT sid="324" pm="."><plain>Elemental analysis found: C, 53.02%; H, 4.45%; N, 25.64%. </plain></SENT>
<SENT sid="325" pm="."><plain>Calculated for C12H11N5O3 (MW 273.25): C, 52.75%; H, 4.06%; N, 25.63%. </plain></SENT>
</text></p></sec><sec id="sec3dot4-molecules-22-00223"><title><text><SENT sid="326" pm="."><plain>3.4. </plain></SENT>
<SENT sid="327" pm="."><plain>Biological Screening </plain></SENT>
</text></title><sec id="sec3dot4dot1-molecules-22-00223"><title><text><SENT sid="328" pm="."><plain>3.4.1. </plain></SENT>
<SENT sid="329" pm="."><plain>Antimycobacterial Evaluation </plain></SENT>
</text></title><p><text><SENT sid="330" pm="."><plain>Antimycobacterial screening was performed against M. tuberculosis H37Rv CNCTC My 331/88, M. kansasii Hauduroy CNCTC My 235/80, and M. avium CNCTC My 152/73 (Czech National Collection of Type Cultures, National Institute of Public Health, Prague, Czech Republic) using isoniazid and pyrazinamide (Sigma-Aldrich) as standards. </plain></SENT>
<SENT sid="331" pm="."><plain>Culturing medium used for assays was Sula’s semisynthetic broth with adjusted pH 5.6 (Trios, Prague, Czech Republic). </plain></SENT>
<SENT sid="332" pm="."><plain>Cultures were grown at 37 °C in the dark and in a humid atmosphere. </plain></SENT>
<SENT sid="333" pm="."><plain>Tested compounds were dissolved in dimethyl sulfoxide (DMSO) and diluted with medium to final concentrations 100, 50, 25, 12.5, 6.25, 3.13 and 1.56 μg/mL except for INH where the dilution continues up to 0.1 μg/mL. </plain></SENT>
<SENT sid="334" pm="."><plain>The method used for this screening was a microdilution broth panel method. </plain></SENT>
<SENT sid="335" pm="."><plain>Mycobacterial inoculum was suspended in sterile water and the density was adjusted in the range between 0.5 and 1.0 McFarland scale. </plain></SENT>
<SENT sid="336" pm="."><plain>Suspensions were diluted with broth by 10−1, added to microtitration plates and incubated for 14 days for M. tuberculosis, 5–7 days for M. kansasii and 5 days for M. avium. </plain></SENT>
<SENT sid="337" pm="."><plain>Drug-free controls were included containing broth with DMSO. </plain></SENT>
<SENT sid="338" pm="."><plain>The final concentration of DMSO was 0.5% (v/v) and did not affect the growth of mycobacteria. </plain></SENT>
<SENT sid="339" pm="."><plain>Antimycobacterial activity was determined using a resazurin-based dye (Alamar blue) and results were read after 24 h of incubation after addition of 30 µL of stain (0.005% solution of resazurin sodium salt in the 1:1 mixture of water and 10% (v/v) water solution of Tween 80) [43]. </plain></SENT>
<SENT sid="340" pm="."><plain>Minimum inhibitory concentration was defined as the lowest concentration of tested compound which prevented colour change (from blue to pink). </plain></SENT>
</text></p><p><text><SENT sid="341" pm="."><plain>Resistant strains were obtained as clinical isolates of M. tuberculosis labelled 234/2005, 9449/2007, Praha 1, Praha 4 and Praha 131. </plain></SENT>
<SENT sid="342" pm="."><plain>Microdilution broth panel method was used to determine MIC. </plain></SENT>
<SENT sid="343" pm="."><plain>Tested compounds were dissolved in DMSO, diluted with Sula’s semisynthetic medium to get final concentrations ranged between 1 and 1000 μM. </plain></SENT>
<SENT sid="344" pm="."><plain>INH was used as a standard in a sterile water solution at a concentration ranging from 0.5 to 250 μM. </plain></SENT>
<SENT sid="345" pm="."><plain>Suspensions of mycobacterial strains were adjusted to density 1.0 according to McFarland scale. </plain></SENT>
<SENT sid="346" pm="."><plain>MIC was determined as the lowest concentration that inhibited the visual growth of mycobacteria after incubation (37 °C) for 14 resp. </plain></SENT>
<SENT sid="347" pm="."><plain>21 days. </plain></SENT>
</text></p></sec><sec id="sec3dot4dot2-molecules-22-00223"><title><text><SENT sid="348" pm="."><plain>3.4.2. </plain></SENT>
<SENT sid="349" pm="."><plain>Evaluation of Activity Against Mycobacterium smegmatis </plain></SENT>
</text></title><p><text><SENT sid="350" pm="."><plain>The antimycobacterial assay was performed with the fast growing Mycobacterium smegmatis CCM 4622 (ATCC 607) from Czech Collection of Microorganisms (Brno, Czech Republic). </plain></SENT>
<SENT sid="351" pm="."><plain>A technique used for activity determination was microdilution broth panel method using 96-well microtitration plates. </plain></SENT>
<SENT sid="352" pm="."><plain>Culturing medium was Middlebrook 7H9 broth (Sigma-Aldrich) enriched with 0.4% of glycerol (Sigma-Aldrich) and 10% of Middlebrook OADC growth supplement (Himedia, Mumbai, India). </plain></SENT>
<SENT sid="353" pm="."><plain>Tested compounds were dissolved in DMSO (Sigma-Aldrich) then Middlebrook broth was added to obtain concentration 2000 µg/mL. </plain></SENT>
<SENT sid="354" pm="."><plain>Standards used for activity determination were isoniazid (INH), rifampicin (RIF) and ciprofloxacin (CPX) (Sigma-Aldrich). </plain></SENT>
<SENT sid="355" pm="."><plain>Final concentrations were reached by binary dilution and addition of mycobacterial suspension and were set as 500, 250, 125, 62.5, 31.25, 15.63, 7.81 and 3.91 µg/mL except to standards ciprofloxacin and rifampicin where the final concentrations were 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.20 and 0.10 µg/mL. </plain></SENT>
<SENT sid="356" pm="."><plain>Drug-free controls were included containing Middlebrook 7H9 broth and DMSO. </plain></SENT>
<SENT sid="357" pm="."><plain>The final concentration of DMSO did not exceeded 2.5% (v/v) and did not affect the growth of M. smegmatis. Mycobacterium smegmatis was cultured in liquid medium Middlebrook 7H9 enriched with glycerol (0.4%) and OADC growth supplement (10%). </plain></SENT>
<SENT sid="358" pm="."><plain>Bacteria were always passaged after seven days of incubation. </plain></SENT>
<SENT sid="359" pm="."><plain>Testing mycobacterial suspension was prepared by adjusting a density to 1.0 McFarland scale and diluting it with broth in a ratio of 1:20. </plain></SENT>
<SENT sid="360" pm="."><plain>Plates were sealed with a polyester adhesive film and incubated at 37 °C in the dark without agitation. </plain></SENT>
<SENT sid="361" pm="."><plain>Addition of 0.01% solution of resazurin sodium salt (20 μL) followed after 48 h of incubation. </plain></SENT>
<SENT sid="362" pm="."><plain>Stain was prepared by dissolving resazurin sodium salt (Sigma-Aldrich) in deionised water to get a 0.02% solution. </plain></SENT>
<SENT sid="363" pm="."><plain>Then 10% aqueous solution of Tween 80 (Sigma-Aldrich) was prepared. </plain></SENT>
<SENT sid="364" pm="."><plain>Both liquids were mixed up making use of the same volumes and filtered through a syringe membrane filter. </plain></SENT>
<SENT sid="365" pm="."><plain>After addition of dye, microtitration panels were then incubated for additional 4 h. </plain></SENT>
<SENT sid="366" pm="."><plain>Antimycobacterial activity was expressed as minimum inhibitory concentration (MIC) and a value was read on the basis of colour change (blue colour—active; pink colour—inactive). </plain></SENT>
<SENT sid="367" pm="."><plain>MIC values for standards were in ranges 7.81–15.63 µg/mL for INH, 0.78–1.56 µg/mL for RIF and 0.10–0.20 µg/mL for CPX. </plain></SENT>
<SENT sid="368" pm="."><plain>All experiments were conducted in duplicate. </plain></SENT>
</text></p></sec><sec id="sec3dot4dot3-molecules-22-00223"><title><text><SENT sid="369" pm="."><plain>3.4.3. </plain></SENT>
<SENT sid="370" pm="."><plain>Antibacterial and Antifungal Activity Evaluation </plain></SENT>
</text></title><p><text><SENT sid="371" pm="."><plain>This assay was based on the microdilution broth panel method in 96-well microtitration plates [44]. </plain></SENT>
<SENT sid="372" pm="."><plain>Organisms used in experiments included strains Staphylococcus aureus CCM 4516/08, Escherichia coli CCM 4517, Pseudomonas aeruginosa CCM 1961 (Czech Collection of Microorganisms, Brno, Czech Republic) that are recommended as standards for antibacterial screening. </plain></SENT>
<SENT sid="373" pm="."><plain>Additional strains were acquired from Department of Clinical Microbiology, University Hospital, Hradec Kralove, Czech Republic as clinical isolates: Staphylococcus aureus H 5996/08—methicillin resistant (MRSA), Staphylococcus epidermidis H 6966/08, Enterococcus faecalis J 14365/08, Klebsiella pneumoniae D 11750/08, Klebsiella pneumoniae J 14368/08—ESBL positive. </plain></SENT>
<SENT sid="374" pm="."><plain>All microorganisms were cultured on Mueller-Hinton agar (MHA) (Difco/Becton Dickinson, Detroit, MI, USA) at 35 °C. </plain></SENT>
<SENT sid="375" pm="."><plain>Bacterial inoculum was prepared by suspending a colony in sterile 0.85% saline. </plain></SENT>
<SENT sid="376" pm="."><plain>The cell density of the inoculum was adjusted to 0.5 McFarland scale. </plain></SENT>
<SENT sid="377" pm="."><plain>Compounds were dissolved in DMSO and antibacterial activity was determined in Mueller-Hinton broth (Difco/Becton Dickinson) buffered to pH 7.0. </plain></SENT>
<SENT sid="378" pm="."><plain>Negative controls (growth controls) were consisted of medium and DMSO. </plain></SENT>
<SENT sid="379" pm="."><plain>The final concentration of DMSO did not exceed 1% (v/v) of the total solution composition. </plain></SENT>
<SENT sid="380" pm="."><plain>Minimum inhibitory concentration (MIC) was defined as inhibition of bacterial growth compared to control and was determined after 24 and 48 h of static incubation at 35 °C. </plain></SENT>
<SENT sid="381" pm="."><plain>Bacitracin, neomycin, ciprofloxacin and phenoxymethylpenicillin were chosen as standards. </plain></SENT>
</text></p><p><text><SENT sid="382" pm="."><plain>Antifungal screening was also carried out using microdilution broth method with tested strains—Candida albicans ATCC 44859, C. tropicalis 156, C. krusei E28, C. glabrata 20/I, Trichosporon asahii 1188, Aspergillus fumigatus 231, Lichtheimia corymbifera 272 and Trichophyton mentagrophytes 445. </plain></SENT>
<SENT sid="383" pm="."><plain>Compounds were dissolved in DMSO and diluted using RPMI 1640 medium with glutamine buffered to pH 7.0 (MOPS) in a twofold manner. </plain></SENT>
<SENT sid="384" pm="."><plain>The final concentration of DMSO in tested medium did not exceed 2.5% (v/v). </plain></SENT>
<SENT sid="385" pm="."><plain>Static incubation was performed at 35 °C in a humid atmosphere in the dark for 24 and 48 h (resp. </plain></SENT>
<SENT sid="386" pm="."><plain>72 and 120 h for Trichophyton mentagrophytes). </plain></SENT>
<SENT sid="387" pm="."><plain>Drug-free controls were included and fluconazole, amphotericin B, voriconazole and nystatin were used as standards [45]. </plain></SENT>
</text></p></sec><sec id="sec3dot4dot4-molecules-22-00223"><title><text><SENT sid="388" pm="."><plain>3.4.4. </plain></SENT>
<SENT sid="389" pm="."><plain>Cytotoxicity Determination </plain></SENT>
</text></title><p><text><SENT sid="390" pm="."><plain>Human hepatocellular liver carcinoma cell line HepG2 (passage 12) purchased from Health Protection Agency Culture Collections (ECACC, Salisbury, UK) was routinely cultured in Minimum Essential Eagle Medium (MEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum (PAA Laboratories GmbH, Pasching, Austria), 1% L-glutamine solution (Sigma-Aldrich) and non-essential amino acid solution (Sigma-Aldrich) in a humid atmosphere containing 5% of CO2 at 37 °C. </plain></SENT>
<SENT sid="391" pm="."><plain>Cells were harvested after trypsin/EDTA (Sigma-Aldrich) treatment at 37 °C for subculturing. </plain></SENT>
<SENT sid="392" pm="."><plain>Cells treated with tested substances were used as experimental groups. </plain></SENT>
<SENT sid="393" pm="."><plain>Untreated HepG2 cells were applied to represent control groups. </plain></SENT>
<SENT sid="394" pm="."><plain>HepG2 cells were seeded in density 10,000 cells per well in a 96-well plates and were treated with tested substances dissolved in DMSO next day. </plain></SENT>
<SENT sid="395" pm="."><plain>The tested compounds were prepared in seven concentrations (1–1000 µM) in triplicates. </plain></SENT>
<SENT sid="396" pm="."><plain>The controls (100% cell viability, 0% cell viability, control without cells, and vehicle controls) were also prepared in triplicates. </plain></SENT>
<SENT sid="397" pm="."><plain>The reagent from CellTiter 96 Aqueous One Solution Cell Proliferation Assay (CellTiter 96, Promega Corporation, Madison, WI, USA) was added after incubation in a humidified atmosphere containing 5% of CO2 at 37 °C lasting for 24 h. </plain></SENT>
<SENT sid="398" pm="."><plain>Additional incubation at 37 °C followed and absorbance was recorded at 490 nm. </plain></SENT>
<SENT sid="399" pm="."><plain>A standard toxicological parameter IC50 was calculated using GraphPad Prism software 6.02 (GraphPad Software, La Jolla, CA, USA). </plain></SENT>
</text></p></sec><sec id="sec3dot4dot5-molecules-22-00223"><title><text><SENT sid="400" pm="."><plain>3.4.5. </plain></SENT>
<SENT sid="401" pm="."><plain>Lipophilicity Determination </plain></SENT>
</text></title><p><text><SENT sid="402" pm="."><plain>Theoretical lipophilicity parameters logP and ClogP were calculated by algorithms of program CS ChemBioDraw Ultra 14.0 (CambridgeSoft, Cambridge, MA, USA). </plain></SENT>
<SENT sid="403" pm="."><plain>Experimental lipophilicity parameter logk values were determined using HPLC method. </plain></SENT>
<SENT sid="404" pm="."><plain>Agilent Technologies 1200 SL liquid chromatography with SL G1315C diode-array detector, ZORBAX XDB-C18 5 μm, 4 × 4 mm, Part No. 7995118-504 chromatographic pre-column and ZORBAX Eclipse XDB-C18 5 μm, 4.6 × 250 mm, Part No. 7995118-585 column (Agilent Technologies Inc., Colorado Springs, CO, USA) were used in the HPLC system. </plain></SENT>
<SENT sid="405" pm="."><plain>The separation process was handled by Agilent ChemStation, version B.04.02 extended with spectral module (Agilent Technologies Inc.). </plain></SENT>
<SENT sid="406" pm="."><plain>A mixture of methanol (HPLC grade, 70%) and water (HPLC-Milli-Q Grade, 30%) was used as mobile phase. </plain></SENT>
<SENT sid="407" pm="."><plain>The total flow rate of the column was set to 1.0 mL/min, injection 20 μL, column temperature 30 °C. </plain></SENT>
<SENT sid="408" pm="."><plain>210 nm as detection wavelength and 270 nm as monitor wavelength were chosen. </plain></SENT>
<SENT sid="409" pm="."><plain>A methanolic solution of KI was used for the determination of dead time (TD). </plain></SENT>
<SENT sid="410" pm="."><plain>Retention times (TR) of synthesized compounds were measured in minutes. </plain></SENT>
<SENT sid="411" pm="."><plain>Capacity factors k were calculated according to formula k = (TR − TD)/TD, where TR is the retention time of the solute and TD denotes the dead time obtained via an unretained analyte (KI). </plain></SENT>
<SENT sid="412" pm="."><plain>Logk, which was calculated from the capacity factor k, is used as the lipophilicity index. </plain></SENT>
</text></p></sec></sec><sec id="sec3dot5-molecules-22-00223"><title><text><SENT sid="413" pm="."><plain>3.5. </plain></SENT>
<SENT sid="414" pm="."><plain>Computational Studies </plain></SENT>
</text></title><p><text><SENT sid="415" pm="."><plain>All molecular modelling was done using Schrödinger Suite (Release 2014-2) and visualizations were prepared in Maestro 9.8 (Schrödinger, LLC, New York, NY, USA). </plain></SENT>
<SENT sid="416" pm="."><plain>Docking was carried out using software Glide (Schrödinger). </plain></SENT>
<SENT sid="417" pm="."><plain>The crystal structure of enzyme enoyl-ACP reductase was prepared using PDB structure 4TZK as starting geometry, using Maestro Protein Preparation Wizard with default settings. </plain></SENT>
<SENT sid="418" pm="."><plain>The ligand and the non-bonding water molecules were removed. </plain></SENT>
<SENT sid="419" pm="."><plain>Restrain energy minimization was performed using OPLS-2005 force field (to gradient of 0.001 RMS kcal/mol/A2). </plain></SENT>
<SENT sid="420" pm="."><plain>Original ligand was used to determine a binding site using grid generation tool. </plain></SENT>
<SENT sid="421" pm="."><plain>The ligand structures were prepared in Maestro 2D sketcher. </plain></SENT>
<SENT sid="422" pm="."><plain>Compounds were subsequently docked using the standard precision (SP) protocol with flexible sampling of ligands and without any constraints. </plain></SENT>
<SENT sid="423" pm="."><plain>Top-scored compounds were subsequently docked using the extra precision (XP) protocol. </plain></SENT>
<SENT sid="424" pm="."><plain>The docking protocol was validated by re-docking the original co-crystalized ligand. </plain></SENT>
<SENT sid="425" pm="."><plain>Average RMSD for five best-scored poses after redocking of the original ligand was 0.85 Å. </plain></SENT>
<SENT sid="426" pm="."><plain>Conformational search for compound 14 was performed using MOE 2016.08 (Molecular Operating Environment, Chemical Computing Group Inc., Montreal, QC, Canada). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec id="sec4-molecules-22-00223"><title><text><SENT sid="427" pm="."><plain>4. </plain></SENT>
<SENT sid="428" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="429" pm="."><plain>Four of fifteen prepared compounds showed notable antimycobacterial activity against M. tuberculosis H37Rv. </plain></SENT>
<SENT sid="430" pm="."><plain>Compounds 4, 8, 9 and 12 exerted activities similar to or better than PZA. </plain></SENT>
<SENT sid="431" pm="."><plain>4‑Methylbenzylamino derivative 8 also showed activity nearly the same as that of the standard isoniazid. </plain></SENT>
<SENT sid="432" pm="."><plain>Prepared benzylaminopyrazine-2-carboxamides were compared to previously synthesized benzylaminopyrazines with different substitution patterns on the pyrazine ring. </plain></SENT>
<SENT sid="433" pm="."><plain>The corresponding compounds were determined to be active, nevertheless the title structures of this research without a carbonitrile moiety appeared to exert at least double activity, even though their lipophilicity was lower. </plain></SENT>
<SENT sid="434" pm="."><plain>Additional screening against resistant strains of M. tbc showed moderate activity for compounds 8 and 9. </plain></SENT>
<SENT sid="435" pm="."><plain>The values were not comparable to substances with proven susceptibility. </plain></SENT>
<SENT sid="436" pm="."><plain>Cytotoxicity assays performed on HepG2 cells confirmed preceding assumption that molecules containing a trifluoromethyl moiety are cytotoxic despite the fact they are usually active. </plain></SENT>
<SENT sid="437" pm="."><plain>On the other hand, compounds 8 and 9 showed very low cytotoxicity and their calculated selectivity index was considered to be propitious. </plain></SENT>
<SENT sid="438" pm="."><plain>Antitubercular activity of these two compounds is rather specific than non-selective based on the cytotoxic effect. </plain></SENT>
<SENT sid="439" pm="."><plain>Docking studies did not exclude that inhibition of InhA might contribute to the mechanism of action of the presented derivatives. </plain></SENT>
<SENT sid="440" pm="."><plain>However, comparison of in vitro and in silico results suggests that InhA inhibition is probably not the main mechanism of action of these 2,3-disubstituted derivatives, or, the disagreement might be caused by differences in mycobacterial cell penetration among individual compounds. </plain></SENT>
<SENT sid="441" pm="."><plain>Nevertheless, predicted binding poses of active derivatives exhibit the key interactions observed with the most of the confirmed InhA inhibitors. </plain></SENT>
<SENT sid="442" pm="."><plain>The pyrazine carboxamide group plays a crucial role by forming the important interactions with Tyr 158 and NAD+. </plain></SENT>
<SENT sid="443" pm="."><plain>Substitution of the pyrazine core seems to determine the affinity of the assessed compounds and further stabilize the possible inhibitor within the active site. </plain></SENT>
<SENT sid="444" pm="."><plain>This enables interactions with various residues within the pocket and therefore anchor the inhibitor in the active site. </plain></SENT>
<SENT sid="445" pm="."><plain>Compounds 8 and 9 are suitable for further structural modifications that might improve their biological properties (activity, cytotoxicity) and physicochemical properties (solubility, lipophilicity). </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="446" pm="."><plain>This study was supported by the Ministry of Education, Youth and Sports of the Czech Republic (SVV 260 291), by Grant Agency of Charles University (project B-CH/1594214), by the Czech Science Foundation (project No. 17-27514Y) and also by the Charles University (project Progres Q42). </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn><p><text><SENT sid="447" pm="."><plain>Sample Availability: Samples of the compounds 1–15 are available from the authors. </plain></SENT>
</text></p></fn></fn-group><notes><title>Author Contributions</title><p>O.J., J.Z. and M.D. conceived and designed the experiments; O.J. and M.T. performed the experiments; O.J. interpreted analytical data and results of anti-infective screening; P.P. and K.K. together with O.J. performed biological assays (antimycobacterial, antibacterial, antifungal); L.N. carried out cytotoxicity screening and interpreted its results; V.K. measured lipophilicity parameters; O.H. performed computational studies together with interpretation of gathered data; O.J. wrote the paper.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><SecTag type="REF"><ref-list><title>References</title><ref id="B1-molecules-22-00223"><text><SENT sid="448" pm="."><plain>1. World Health Organization Global Tuberculosis Report 2016 WHO Press Geneva, Switzerland 2016 WHO/HTM/TB/2016.13 978 92 4 156539 4  </plain></SENT>
</text></ref><ref id="B2-molecules-22-00223"><text><SENT sid="449" pm="."><plain>2. PalominoJ.C.MartinA. TMC207 becomes bedaquiline, a new anti-TB drug Future Microbiol. 2013 8 1071 1080 10.2217/fmb.13.85 <?supplied-pmid 24020736?>24020736 </plain></SENT>
</text></ref><ref id="B3-molecules-22-00223"><text><SENT sid="450" pm="."><plain>3. ZhangY.MitchisonD. The curious characteristics of pyrazinamide: A review Int. </plain></SENT>
<SENT sid="451" pm="."><plain>J. </plain></SENT>
<SENT sid="452" pm="."><plain>Tuberc. </plain></SENT>
<SENT sid="453" pm="."><plain>Lung Dis. 2003 7 6 21 <?supplied-pmid 12701830?>12701830 </plain></SENT>
</text></ref><ref id="B4-molecules-22-00223"><text><SENT sid="454" pm="."><plain>4. ZhangY.WadeM.M.ScorpioA.ZhangH.SunZ. Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid J. </plain></SENT>
<SENT sid="455" pm="."><plain>Antimicrob. </plain></SENT>
<SENT sid="456" pm="."><plain>Chemother. 2003 52 790 795 10.1093/jac/dkg446 <?supplied-pmid 14563891?>14563891 </plain></SENT>
</text></ref><ref id="B5-molecules-22-00223"><text><SENT sid="457" pm="."><plain>5. PetersonN.D.RosenB.C.DillonN.A.BaughnA.D. Uncoupling environmental pH and intrabacterial acidification from pyrazinamide susceptibility in Mycobacterium tuberculosis Antimicrob. </plain></SENT>
<SENT sid="458" pm="."><plain>Agents Chemother. 2015 59 7320 7326 10.1128/AAC.00967-15 <?supplied-pmid 26369957?>26369957 </plain></SENT>
</text></ref><ref id="B6-molecules-22-00223"><text><SENT sid="459" pm="."><plain>6. SayahiH.ZimhonyO.JacobsW.R.ShekthmanA.WelchJ.T. Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I Bioorg. </plain></SENT>
<SENT sid="460" pm="."><plain>Med. </plain></SENT>
<SENT sid="461" pm="."><plain>Chem. </plain></SENT>
<SENT sid="462" pm="."><plain>Lett. 2011 21 4804 4807 10.1016/j.bmcl.2011.06.055 <?supplied-pmid 21775138?>21775138 </plain></SENT>
</text></ref><ref id="B7-molecules-22-00223"><text><SENT sid="463" pm="."><plain>7. ShiW.L.ZhangX.L.JiangX.YuanH.M.LeeJ.S.BarryC.E.WangH.H.ZhangW.H.ZhangY. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 2011 333 1630 1632 10.1126/science.1208813 <?supplied-pmid 21835980?>21835980 </plain></SENT>
</text></ref><ref id="B8-molecules-22-00223"><text><SENT sid="464" pm="."><plain>8. ShiW.ChenJ.FengJ.CuiP.ZhangS.WengX.ZhangW.ZhangY. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis Emerg. </plain></SENT>
<SENT sid="465" pm="."><plain>Microbes Infect. 2014 3 e58 10.1038/emi.2014.61 <?supplied-pmid 26038753?>26038753 </plain></SENT>
</text></ref><ref id="B9-molecules-22-00223"><text><SENT sid="466" pm="."><plain>9. ZitkoJ.DolezalM.SvobodovaM.VejsovaM.KunesJ.KuceraR.JilekP. Synthesis and antimycobacterial properties of N-substituted-6-amino-5-cyanopyrazine-2-carboxamides Bioorg. </plain></SENT>
<SENT sid="467" pm="."><plain>Med. </plain></SENT>
<SENT sid="468" pm="."><plain>Chem. 2011 19 1471 1476 10.1016/j.bmc.2010.12.054 <?supplied-pmid 21273083?>21273083 </plain></SENT>
</text></ref><ref id="B10-molecules-22-00223"><text><SENT sid="469" pm="."><plain>10. ZitkoJ.JampilekJ.DobrovolnyL.SvobodovaM.KunesJ.DolezalM. Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles Bioorg. </plain></SENT>
<SENT sid="470" pm="."><plain>Med. </plain></SENT>
<SENT sid="471" pm="."><plain>Chem. </plain></SENT>
<SENT sid="472" pm="."><plain>Lett. 2012 22 1598 1601 10.1016/j.bmcl.2011.12.129 <?supplied-pmid 22281187?>22281187 </plain></SENT>
</text></ref><ref id="B11-molecules-22-00223"><text><SENT sid="473" pm="."><plain>11. ServusovaB.PaterovaP.MandikovaJ.KubicekV.KuceraR.KunesJ.DolezalM.ZitkoJ. Alkylamino derivatives of pyrazinamide: Synthesis and antimycobacterial evaluation Bioorg. </plain></SENT>
<SENT sid="474" pm="."><plain>Med. </plain></SENT>
<SENT sid="475" pm="."><plain>Chem. </plain></SENT>
<SENT sid="476" pm="."><plain>Lett. 2014 24 450 453 10.1016/j.bmcl.2013.12.054 <?supplied-pmid 24388809?>24388809 </plain></SENT>
</text></ref><ref id="B12-molecules-22-00223"><text><SENT sid="477" pm="."><plain>12. ZitkoJ.ServusovaB.JanoutovaA.PaterovaP.MandikovaJ.GarajV.VejsovaM.MarekJ.DolezalM. Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides Bioorg. </plain></SENT>
<SENT sid="478" pm="."><plain>Med. </plain></SENT>
<SENT sid="479" pm="."><plain>Chem. 2015 23 174 183 10.1016/j.bmc.2014.11.014 <?supplied-pmid 25438883?>25438883 </plain></SENT>
</text></ref><ref id="B13-molecules-22-00223"><text><SENT sid="480" pm="."><plain>13. Servusova-VanaskovaB.JandourekO.PaterovaP.KordulakovaJ.PlevakovaM.KubicekV.KuceraR.GarajV.NaesensL.KunesJ. Alkylamino derivatives of N-benzylpyrazine-2-carboxamide: synthesis and antimycobacterial evaluation MedChemComm 2015 6 1311 1317 10.1039/C5MD00178A  </plain></SENT>
</text></ref><ref id="B14-molecules-22-00223"><text><SENT sid="481" pm="."><plain>14. ServusovaB.EibinovaD.DolezalM.KubicekV.PaterovaP.PeskoM.KralovaK. Substituted N-benzylpyrazine-2-carboxamides: Synthesis and biological evaluation Molecules 2012 17 13183 13198 10.3390/molecules171113183 <?supplied-pmid 23132136?>23132136 </plain></SENT>
</text></ref><ref id="B15-molecules-22-00223"><text><SENT sid="482" pm="."><plain>15. ServusovaB.VobickovaJ.PaterovaP.KubicekV.KunesJ.DolezalM.ZitkoJ. Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides Bioorg. </plain></SENT>
<SENT sid="483" pm="."><plain>Med. </plain></SENT>
<SENT sid="484" pm="."><plain>Chem. </plain></SENT>
<SENT sid="485" pm="."><plain>Lett. 2013 23 3589 3591 10.1016/j.bmcl.2013.04.021 <?supplied-pmid 23659859?>23659859 </plain></SENT>
</text></ref><ref id="B16-molecules-22-00223"><text><SENT sid="486" pm="."><plain>16. ZitkoJ.PaterovaP.KubicekV.MandikovaJ.TrejtnarF.KunesJ.DolezalM. Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution Bioorg. </plain></SENT>
<SENT sid="487" pm="."><plain>Med. </plain></SENT>
<SENT sid="488" pm="."><plain>Chem. </plain></SENT>
<SENT sid="489" pm="."><plain>Lett. 2013 23 476 479 10.1016/j.bmcl.2012.11.052 <?supplied-pmid 23237840?>23237840 </plain></SENT>
</text></ref><ref id="B17-molecules-22-00223"><text><SENT sid="490" pm="."><plain>17. JandourekO.DolezalM.PaterovaP.KubicekV.PeskoM.KunesJ.CoffeyA.GuoJ.KralovaK. N-Substituted 5-amino-6-methylpyrazine-2,3-dicarbonitriles: Microwave-assisted synthesis and biological properties Molecules 2014 19 651 671 10.3390/molecules19010651 <?supplied-pmid 24402198?>24402198 </plain></SENT>
</text></ref><ref id="B18-molecules-22-00223"><text><SENT sid="491" pm="."><plain>18. HayesB.L. Microwave Synthesis: Chemistry at the Speed of Light CEM Pub. Matthews, NC, USA 2002  </plain></SENT>
</text></ref><ref id="B19-molecules-22-00223"><text><SENT sid="492" pm="."><plain>19. JandourekO.DolezalM.KlementovaM.KralovaK.PeskoM. Microwave assisted synthesis of new pyrazinamide analogues and their biological evaluation Proceedings of the 16th International Electronic Conference on Synthetic Organic Chemistry 29 November 2012 Sciforum Electronic Conference Series MDPI Basel, Switzerland 2012 16 12  </plain></SENT>
</text></ref><ref id="B20-molecules-22-00223"><text><SENT sid="493" pm="."><plain>20. KralovaK.PeskoM.PaterovaP.KunesJ.TauchmanM.EibinovaD.CarilloC.ZitkoJ.DolezalM. Substituted N-benzylpyrazine-2-carboxamides, Their Synthesis, Hydro-lipophilic Properties and Evaluation of Their Antimycobacterial and Photosynthesis-inhibiting Activities Proceedings of the 15th International Electronic Conference on Synthetic Organic Chemistry 1–30 November 2011 Sciforum Electronic Conference Series MDPI Basel, Switzerland 2011 15 6  </plain></SENT>
</text></ref><ref id="B21-molecules-22-00223"><text><SENT sid="494" pm="."><plain>21. KuoM.R.MorbidoniM.R.AllandD.SneddonS.F.GourlieB.B.StaveskiM.M.LeonardM.GregoryJ.S.JanjigianA.D.YeeC. Targeting tuberculosis and malaria through inhibition of enoyl reductase compound activity and structural data J. </plain></SENT>
<SENT sid="495" pm="."><plain>Biol. </plain></SENT>
<SENT sid="496" pm="."><plain>Chem. 2003 278 20851 20859 10.1074/jbc.M211968200 <?supplied-pmid 12606558?>12606558 </plain></SENT>
</text></ref><ref id="B22-molecules-22-00223"><text><SENT sid="497" pm="."><plain>22. GhattasM.A.MansourR.A.AtatrehN.BryceR.A. Analysis of Enoyl-Acyl Carrier Protein Reductase Structure and Interactions Yields an Efficient Virtual Screening Approach and Suggests a Potential Allosteric Site Chem. </plain></SENT>
<SENT sid="498" pm="."><plain>Biol. </plain></SENT>
<SENT sid="499" pm="."><plain>Drug Des. 2016 87 131 142 10.1111/cbdd.12635 <?supplied-pmid 26259619?>26259619 </plain></SENT>
</text></ref><ref id="B23-molecules-22-00223"><text><SENT sid="500" pm="."><plain>23. YangJ.LiuY.BiJ.CaiQ.LiaoX.LiW.GuoC.ZhangQ.LinT.ZhaoY. Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide Mol. </plain></SENT>
<SENT sid="501" pm="."><plain>Microbiol. 2015 95 791 803 10.1111/mmi.12892 <?supplied-pmid 25430994?>25430994 </plain></SENT>
</text></ref><ref id="B24-molecules-22-00223"><text><SENT sid="502" pm="."><plain>24. PetrellaS.Gelus-ZientalN.MaudryA.LauransC.BoudjelloulR.SougakoffW. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide PLoS ONE 2011 6 e15785 10.1371/journal.pone.0015785 <?supplied-pmid 21283666?>21283666 </plain></SENT>
</text></ref><ref id="B25-molecules-22-00223"><text><SENT sid="503" pm="."><plain>25. PandeyB.GroverS.TyagiC.GoyalS.JamalS.SinghA.KaurJ.GroverA. Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis Gene 2016 581 31 42 10.1016/j.gene.2016.01.024 <?supplied-pmid 26784657?>26784657 </plain></SENT>
</text></ref><ref id="B26-molecules-22-00223"><text><SENT sid="504" pm="."><plain>26. CiccarelliL.ConnellS.R.EnderleM.MillsD.J.VonckJ.GriningerM. Structure and conformational variability of the Mycobacterium tuberculosis fatty acid synthase multienzyme complex Structure 2013 21 1251 1257 10.1016/j.str.2013.04.023 <?supplied-pmid 23746808?>23746808 </plain></SENT>
</text></ref><ref id="B27-molecules-22-00223"><text><SENT sid="505" pm="."><plain>27. DlabalK.PalatK.LyckaA.OdlerovaZ. Synthesis and 1H and 13C NMR spectra of sulfur derivatives of pyrazine derived from amidation product of 2-chloropyrazine and 6-chloro-2-pyrazinecarbonitrile. </plain></SENT>
<SENT sid="506" pm="."><plain>Tuberculostatic activity Collect. </plain></SENT>
<SENT sid="507" pm="."><plain>Czech Chem. </plain></SENT>
<SENT sid="508" pm="."><plain>Commun. 1990 55 2493 2500 10.1135/cccc19902493  </plain></SENT>
</text></ref><ref id="B28-molecules-22-00223"><text><SENT sid="509" pm="."><plain>28. JampilekJ.DolezalM.KunesJ.SatinskyD.RaichI. Novel regioselective preparation of 5-chloropyrazine-2-carbonitrile from pyrazine-2-carboxamide and coupling study of substituted phenylsulfanylpyrazine-2-carboxylic acid derivatives Curr. </plain></SENT>
<SENT sid="510" pm="."><plain>Org. </plain></SENT>
<SENT sid="511" pm="."><plain>Chem. 2005 9 49 60 10.2174/1385272053369312  </plain></SENT>
</text></ref><ref id="B29-molecules-22-00223"><text><SENT sid="512" pm="."><plain>29. JandourekO.DolezalM.KunesJ. Microwave-Assisted Synthesis of Pyrazinamide Derivatives: The Coupling Reaction of 3-Chloropyrazine-2-Carboxamide and Ring-Substituted Anilines Curr. </plain></SENT>
<SENT sid="513" pm="."><plain>Org. </plain></SENT>
<SENT sid="514" pm="."><plain>Synth. 2015 12 189 196 10.2174/1570179411999141106101501  </plain></SENT>
</text></ref><ref id="B30-molecules-22-00223"><text><SENT sid="515" pm="."><plain>30. EbeidF.M.GheitA.K.A.EzzoE.M.AliL.I. Decomposition of Triethylamine over Acid Catalysts J. </plain></SENT>
<SENT sid="516" pm="."><plain>Chin. </plain></SENT>
<SENT sid="517" pm="."><plain>Chem. </plain></SENT>
<SENT sid="518" pm="."><plain>Soc.-Taip. 1982 29 125 129 10.1002/jccs.198200020  </plain></SENT>
</text></ref><ref id="B31-molecules-22-00223"><text><SENT sid="519" pm="."><plain>31. DickinsonJ.M.MitchisonD.A. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis Tubercle 1970 51 389 396 10.1016/0041-3879(70)90004-8 4992755 </plain></SENT>
</text></ref><ref id="B32-molecules-22-00223"><text><SENT sid="520" pm="."><plain>32. McDermottW.TomsettR. Activation of pyrazinamide and nicotinamide in acidic environments in vitro Am. </plain></SENT>
<SENT sid="521" pm="."><plain>Rev. </plain></SENT>
<SENT sid="522" pm="."><plain>Tuberc. 1954 70 748 754 <?supplied-pmid 13197751?>13197751 </plain></SENT>
</text></ref><ref id="B33-molecules-22-00223"><text><SENT sid="523" pm="."><plain>33. HeifetsL.Lindholm-LevyP. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations Am. </plain></SENT>
<SENT sid="524" pm="."><plain>Rev. </plain></SENT>
<SENT sid="525" pm="."><plain>Respir. </plain></SENT>
<SENT sid="526" pm="."><plain>Dis. 1992 145 1223 1225 10.1164/ajrccm/145.5.1223 <?supplied-pmid 1586071?>1586071 </plain></SENT>
</text></ref><ref id="B34-molecules-22-00223"><text><SENT sid="527" pm="."><plain>34. ButlerW.R.KilburnJ.O. Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide J. </plain></SENT>
<SENT sid="528" pm="."><plain>Clin. </plain></SENT>
<SENT sid="529" pm="."><plain>Microbiol. 1982 16 1106 1109 <?supplied-pmid 6819309?>6819309 </plain></SENT>
</text></ref><ref id="B35-molecules-22-00223"><text><SENT sid="530" pm="."><plain>35. PortaelsF.PattynS.R. Growth of mycobacteria in relation to the pH of the medium Ann. </plain></SENT>
<SENT sid="531" pm="."><plain>Microbiol. 1982 133 213 221  </plain></SENT>
</text></ref><ref id="B36-molecules-22-00223"><text><SENT sid="532" pm="."><plain>36. SulaJ. WHO Co-operative studies on a simple culture technique for the isolation of mycobacteria: 1. </plain></SENT>
<SENT sid="533" pm="."><plain>Preparation, lyophilization and reconstitution of a simple semi-synthetic concentrated liquid medium; culture technique; growth pattern of different mycobacteria Bull. </plain></SENT>
<SENT sid="534" pm="."><plain>Wld. </plain></SENT>
<SENT sid="535" pm="."><plain>Hlth. </plain></SENT>
<SENT sid="536" pm="."><plain>Org. 1963 29 589 606  </plain></SENT>
</text></ref><ref id="B37-molecules-22-00223"><text><SENT sid="537" pm="."><plain>37. SulaJ.SundaresanT.K. WHO Co-operative studies on a simple culture technique for the isolation of mycobacteria: 2. </plain></SENT>
<SENT sid="538" pm="."><plain>Comparison of the efficacy of lyophilized liquid medium with that of Löwenstein-Jensen (LJ) medium Bull. </plain></SENT>
<SENT sid="539" pm="."><plain>Wld. </plain></SENT>
<SENT sid="540" pm="."><plain>Hlth. </plain></SENT>
<SENT sid="541" pm="."><plain>Org. 1963 29 607 625  </plain></SENT>
</text></ref><ref id="B38-molecules-22-00223"><text><SENT sid="542" pm="."><plain>38. AlegreO.S. Estudio comparativo de las posibilidades de los medios de Löwenstein-Jensen y liofilizado reconsititudo de Sula para el aislamiento del Myocbaterium tuberculosis Bol. </plain></SENT>
<SENT sid="543" pm="."><plain>Oficina Sanit. </plain></SENT>
<SENT sid="544" pm="."><plain>Panam. 1967 63 13 16 <?supplied-pmid 4235866?>4235866 </plain></SENT>
</text></ref><ref id="B39-molecules-22-00223"><text><SENT sid="545" pm="."><plain>39. ZitkoJ.ServusovaB.PaterovaP.MandikovaJ.KubicekV.KuceraR.HrabcovaV.KunesJ.SoukupO.DolezalM. Synthesis, antimycobacterial activity and in vitro cytotoxicity of 5-chloro-N-phenylpyrazine-2-carboxamides Molecules 2013 18 14807 14825 10.3390/molecules181214807 <?supplied-pmid 24317522?>24317522 </plain></SENT>
</text></ref><ref id="B40-molecules-22-00223"><text><SENT sid="546" pm="."><plain>40. BielenicaA.StefańskaJ.StępieńK.NapiórkowskaA.Augustynowicz-KopećE.SannaG.MadedduS.BoiS.GilibertiG.WrzosekM. Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl) phenyl moiety Eur. </plain></SENT>
<SENT sid="547" pm="."><plain>J. </plain></SENT>
<SENT sid="548" pm="."><plain>Med. </plain></SENT>
<SENT sid="549" pm="."><plain>Chem. 2015 101 111 125 10.1016/j.ejmech.2015.06.027 <?supplied-pmid 26119992?>26119992 </plain></SENT>
</text></ref><ref id="B41-molecules-22-00223"><text><SENT sid="550" pm="."><plain>41. KratkyM.VinsovaJ.NovotnaE.MandikovaJ.TrejtnarF.StolarikovaJ. Antibacterial activity of salicylanilide 4-(trifluoromethyl)-benzoates Molecules 2013 18 3674 3688 10.3390/molecules18043674 <?supplied-pmid 23529028?>23529028 </plain></SENT>
</text></ref><ref id="B42-molecules-22-00223"><text><SENT sid="551" pm="."><plain>42. KeirW.F.MacLennanA.H.WoodH.C. Amidinoacetamides in the synthesis of pyrazines and pteridines J. </plain></SENT>
<SENT sid="552" pm="."><plain>Chem. </plain></SENT>
<SENT sid="553" pm="."><plain>Soc. </plain></SENT>
<SENT sid="554" pm="."><plain>Perk. </plain></SENT>
<SENT sid="555" pm="."><plain>T. </plain></SENT>
<SENT sid="556" pm="."><plain>1 1977 11 1321 1325 10.1039/p19770001321  </plain></SENT>
</text></ref><ref id="B43-molecules-22-00223"><text><SENT sid="557" pm="."><plain>43. FranzblauS.G.WitzigR.S.McLaughlinJ.C.TorresP.MadicoG.HernandezA.DegnanM.T.CookM.B.QuenzerV.K.FergusonR.M. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay J. </plain></SENT>
<SENT sid="558" pm="."><plain>Clin. </plain></SENT>
<SENT sid="559" pm="."><plain>Microbiol. 1998 36 362 366 <?supplied-pmid 9466742?>9466742 </plain></SENT>
</text></ref><ref id="B44-molecules-22-00223"><text><SENT sid="560" pm="."><plain>44. JonesR.N.BarryA.L. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination J. </plain></SENT>
<SENT sid="561" pm="."><plain>Clin. </plain></SENT>
<SENT sid="562" pm="."><plain>Microbiol. 1987 25 1920 1925 <?supplied-pmid 3117843?>3117843 </plain></SENT>
</text></ref><ref id="B45-molecules-22-00223"><text><SENT sid="563" pm="."><plain>45. National Committee for Clinical Laboratory Standards Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Proposed Standard M 27-P National Committee for Clinical Laboratory Standards Villanova, PA, USA 1992  </plain></SENT>
</text></ref></ref-list></SecTag><sec sec-type="display-objects"><title>Figures, Scheme and Tables</title><SecTag type="FIG"><fig id="molecules-22-00223-f001" position="float"><label>Figure 1</label><caption><p><text><SENT sid="564" pm="."><plain>General structures of discussed compounds (A, B—Zitko et al. [16]; C—Jandourek et al. [17]; D—this work) and best MICs against M. tbc H37Rv. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-22-00223-g001"/></fig></SecTag><SecTag type="FIG"><fig id="molecules-22-00223-sch001" position="float"><object-id pub-id-type="pii">molecules-22-00223-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p><text><SENT sid="565" pm="."><plain>Synthesis of the starting compound 3-chloropyrazine-2-carboxamide and its amino-dehalogenation reactions with variously substituted benzylamines carried out under different conditions. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-22-00223-sch001"/></fig></SecTag><SecTag type="FIG"><fig id="molecules-22-00223-f002" position="float"><label>Figure 2</label><caption><p><text><SENT sid="566" pm="."><plain>Dependency of antimycobacterial activity (1/MIC) on experimental parameter of lipophilicity logk. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-22-00223-g002"/></fig></SecTag><SecTag type="FIG"><fig id="molecules-22-00223-f003" position="float"><label>Figure 3</label><caption><p><text><SENT sid="567" pm="."><plain>Linear dependencies of two differently calculated lipophilicity parameters on experimentally measured values. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-22-00223-g003"/></fig></SecTag><SecTag type="FIG"><fig id="molecules-22-00223-f004" position="float"><label>Figure 4</label><caption><p><text><SENT sid="568" pm="."><plain>2D visualization of (a) compound 8 and (b) compound 12 in active site of InhA showing interactions with the substrate binding loop. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-22-00223-g004"/></fig></SecTag><SecTag type="FIG"><fig id="molecules-22-00223-f005" position="float"><label>Figure 5</label><caption><p><text><SENT sid="569" pm="."><plain>Chemical structure of PT70. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-22-00223-g005"/></fig></SecTag><SecTag type="FIG"><fig id="molecules-22-00223-f006" position="float"><label>Figure 6</label><caption><p><text><SENT sid="570" pm="."><plain>The most active compounds docked into the active site of InhA (enoyl-ACP reductase) (4—orange; 8—yellow; 9—aquamarine; 12—green). </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-22-00223-g006"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="molecules-22-00223-t001" position="float"><object-id pub-id-type="pii">molecules-22-00223-t001_Table 1</object-id><label>Table 1</label><caption><p><text><SENT sid="571" pm="."><plain>Summary of prepared compounds, calculated and measured parameters of lipophilicity, results of antimycobacterial and antibacterial evaluation expressed as minimum inhibitory concentration (MIC) compared to standards. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><text><SENT sid="572" pm="."><plain>No. </plain></SENT>
</text></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><text><SENT sid="573" pm="."><plain>R </plain></SENT>
</text></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><text><SENT sid="574" pm="."><plain>MW </plain></SENT>
</text></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><text><SENT sid="575" pm="."><plain>LogP/ClogP </plain></SENT>
</text></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><text><SENT sid="576" pm="."><plain>Logk </plain></SENT>
</text></th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><text><SENT sid="577" pm="."><plain>Minimum Inhibitory Concentrations </plain></SENT>
</text></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="578" pm="."><plain>M. tbc H37Rv (µg/mL) </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="579" pm="."><plain>M. tbc H37Rv (µM) </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="580" pm="."><plain>M. smegmatis (µg/mL) </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="581" pm="."><plain>Bacteria (µM) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="582" pm="."><plain>1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="583" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="584" pm="."><plain>228.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="585" pm="."><plain>0.63/1.64 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="586" pm="."><plain>0.215 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="587" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="588" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="589" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="590" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="591" pm="."><plain>2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="592" pm="."><plain>3-Cl </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="593" pm="."><plain>262.69 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="594" pm="."><plain>1.19/2.36 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="595" pm="."><plain>0.373 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="596" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="597" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="598" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="599" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="600" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="601" pm="."><plain>3,4-Cl </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="602" pm="."><plain>298.14 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="603" pm="."><plain>1.75/2.95 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="604" pm="."><plain>0.470 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="605" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="606" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="607" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="608" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="609" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="610" pm="."><plain>3-CF3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="611" pm="."><plain>297.14 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="612" pm="."><plain>1.56/2.53 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="613" pm="."><plain>0.403 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="614" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="615" pm="."><plain>42 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="616" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="617" pm="."><plain>31.25 SA a </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="618" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="619" pm="."><plain>4-Cl </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="620" pm="."><plain>262.69 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="621" pm="."><plain>1.19/2.36 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="622" pm="."><plain>0.373 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="623" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="624" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="625" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="626" pm="."><plain>250 SA a </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="627" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="628" pm="."><plain>2-CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="629" pm="."><plain>242.28 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="630" pm="."><plain>1.12/2.09 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="631" pm="."><plain>0.320 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="632" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="633" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="634" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="635" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="636" pm="."><plain>7 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="637" pm="."><plain>4-OCH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="638" pm="."><plain>258.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="639" pm="."><plain>0.51/1.56 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="640" pm="."><plain>0.194 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="641" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="642" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="643" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="644" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="645" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="646" pm="."><plain>4-CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="647" pm="."><plain>242.28 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="648" pm="."><plain>1.12/2.14 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="649" pm="."><plain>0.441 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="650" pm="."><plain>1.56 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="651" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="652" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="653" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="654" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="655" pm="."><plain>4-NH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="656" pm="."><plain>243.26 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="657" pm="."><plain>−0.17/0.42 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="658" pm="."><plain>−0.313 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="659" pm="."><plain>6.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="660" pm="."><plain>26 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="661" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="662" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="663" pm="."><plain>10 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="664" pm="."><plain>2-Cl </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="665" pm="."><plain>262.69 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="666" pm="."><plain>1.19/2.36 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="667" pm="."><plain>0.441 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="668" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="669" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="670" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="671" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="672" pm="."><plain>11 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="673" pm="."><plain>2-F </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="674" pm="."><plain>246.24 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="675" pm="."><plain>0.79/1.79 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="676" pm="."><plain>0.248 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="677" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="678" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="679" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="680" pm="."><plain>125 EF b </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="681" pm="."><plain>12 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="682" pm="."><plain>4-CF3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="683" pm="."><plain>296.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="684" pm="."><plain>1.56/2.53 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="685" pm="."><plain>0.502 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="686" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="687" pm="."><plain>42 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="688" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="689" pm="."><plain>125 EF b </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="690" pm="."><plain>13 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="691" pm="."><plain>2-CF3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="692" pm="."><plain>296.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="693" pm="."><plain>1.56/2.53 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="694" pm="."><plain>0.495 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="695" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="696" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="697" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="698" pm="."><plain>125 EF b </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="699" pm="."><plain>14 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="700" pm="."><plain>2,4-OCH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="701" pm="."><plain>288.30 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="702" pm="."><plain>0.38/1.65 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="703" pm="."><plain>0.274 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="704" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="705" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="706" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="707" pm="."><plain>62.5 EF b </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="708" pm="."><plain>15 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="709" pm="."><plain>3-NO2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="710" pm="."><plain>273.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="711" pm="."><plain>n.d./1.39 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="712" pm="."><plain>0.101 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="713" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="714" pm="."><plain>n.a. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="715" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="716" pm="."><plain>&gt;500 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="717" pm="."><plain>INH </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="718" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="719" pm="."><plain>137.14 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="720" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="721" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="722" pm="."><plain>0.39 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="723" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="724" pm="."><plain>7.81–15.63 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="725" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="726" pm="."><plain>PZA </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="727" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="728" pm="."><plain>123.12 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="729" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="730" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="731" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="732" pm="."><plain>102 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="733" pm="."><plain>≥500 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="734" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="735" pm="."><plain>RFM </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="736" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="737" pm="."><plain>822.94 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="738" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="739" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="740" pm="."><plain>n.d. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="741" pm="."><plain>n.d. </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="742" pm="."><plain>0.78–1.56 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="743" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="744" pm="."><plain>CPX </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="745" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="746" pm="."><plain>331.37 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="747" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="748" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="749" pm="."><plain>n.d. </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="750" pm="."><plain>n.d. </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="751" pm="."><plain>0.10–0.20 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="752" pm="."><plain>- </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="753" pm="."><plain>a Staphylococcus aureus CCM 4516/08; b Enterococcus faecalis J 14365/08. </plain></SENT>
<SENT sid="754" pm="."><plain>LogP/ClogP—calc. parameter of lipophilicity (ChemDraw 15.0); Logk—experiment. determined lipophilicity; n.a.—not active; n.d.—not determined. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="molecules-22-00223-t002" position="float"><object-id pub-id-type="pii">molecules-22-00223-t002_Table 2</object-id><label>Table 2</label><caption><p><text><SENT sid="755" pm="."><plain>Summary of prepared compounds, calculated and measured parameters of lipophilicity, results of antimycobacterial and antibacterial evaluation expressed as minimum inhibitory concentration (MIC) compared to standards. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><text></text></th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><text><SENT sid="756" pm="."><plain> </plain></SENT>
</text></th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><text><SENT sid="757" pm="."><plain>MIC against M. tbc H37Rv </plain></SENT>
</text></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="758" pm="."><plain>No. </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="759" pm="."><plain>R </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="760" pm="."><plain>R2 </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="761" pm="."><plain>R5 </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="762" pm="."><plain>R6 </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="763" pm="."><plain>µg/mL </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="764" pm="."><plain>µM </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="765" pm="."><plain>1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="766" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="767" pm="."><plain>CONH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="768" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="769" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="770" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="771" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="772" pm="."><plain>1-A </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="773" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="774" pm="."><plain>CONH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="775" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="776" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="777" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="778" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="779" pm="."><plain>1-B </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="780" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="781" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="782" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="783" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="784" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="785" pm="."><plain>78 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="786" pm="."><plain>1-C </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="787" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="788" pm="."><plain>CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="789" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="790" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="791" pm="."><plain>25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="792" pm="."><plain>100 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="793" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="794" pm="."><plain>3-CF3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="795" pm="."><plain>CONH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="796" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="797" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="798" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="799" pm="."><plain>42 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="800" pm="."><plain>4-A </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="801" pm="."><plain>3-CF3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="802" pm="."><plain>CONH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="803" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="804" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="805" pm="."><plain>25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="806" pm="."><plain>78 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="807" pm="."><plain>4-B </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="808" pm="."><plain>3-CF3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="809" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="810" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="811" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="812" pm="."><plain>&gt;100 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="813" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="814" pm="."><plain>4-C </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="815" pm="."><plain>3-CF3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="816" pm="."><plain>CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="817" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="818" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="819" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="820" pm="."><plain>39 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="821" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="822" pm="."><plain>4-CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="823" pm="."><plain>CONH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="824" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="825" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="826" pm="."><plain>1.56 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="827" pm="."><plain>6 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="828" pm="."><plain>8-A </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="829" pm="."><plain>4-CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="830" pm="."><plain>CONH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="831" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="832" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="833" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="834" pm="."><plain>47 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="835" pm="."><plain>8-B </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="836" pm="."><plain>4-CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="837" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="838" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="839" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="840" pm="."><plain>6.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="841" pm="."><plain>25 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="842" pm="."><plain>8-C </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="843" pm="."><plain>4-CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="844" pm="."><plain>CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="845" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="846" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="847" pm="."><plain>25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="848" pm="."><plain>95 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="849" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="850" pm="."><plain>4-NH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="851" pm="."><plain>CONH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="852" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="853" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="854" pm="."><plain>6.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="855" pm="."><plain>26 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="856" pm="."><plain>9-A </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="857" pm="."><plain>4-NH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="858" pm="."><plain>CONH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="859" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="860" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="861" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="862" pm="."><plain>47 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="863" pm="."><plain>9-B </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="864" pm="."><plain>4-NH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="865" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="866" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="867" pm="."><plain>H </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="868" pm="."><plain>25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="869" pm="."><plain>100 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="870" pm="."><plain>9-C </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="871" pm="."><plain>4-NH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="872" pm="."><plain>CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="873" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="874" pm="."><plain>CN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="875" pm="."><plain>25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="876" pm="."><plain>95 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="877" pm="."><plain>INH </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="878" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="879" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="880" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="881" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="882" pm="."><plain>0.39 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="883" pm="."><plain>3 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="884" pm="."><plain>PZA </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="885" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="886" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="887" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="888" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="889" pm="."><plain>12.5 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="890" pm="."><plain>102 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="molecules-22-00223-t003" position="float"><object-id pub-id-type="pii">molecules-22-00223-t003_Table 3</object-id><label>Table 3</label><caption><p><text><SENT sid="891" pm="."><plain>Activity of two leading compounds 8 and 9 against resistant Mycobacterium tuberculosis strains presented as MIC values. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><text><SENT sid="892" pm="."><plain>No. </plain></SENT>
</text></th><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><text><SENT sid="893" pm="."><plain>R </plain></SENT>
</text></th><th colspan="10" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><text><SENT sid="894" pm="."><plain>Minimum inhibitory concentrations [µM] </plain></SENT>
</text></th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><text><SENT sid="895" pm="."><plain>M. tbc 9449/2007 </plain></SENT>
</text></th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><text><SENT sid="896" pm="."><plain>M. tbc 234/2005 </plain></SENT>
</text></th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><text><SENT sid="897" pm="."><plain>M. tbc PRAHA 1 </plain></SENT>
</text></th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><text><SENT sid="898" pm="."><plain>M. tbc PRAHA 4 </plain></SENT>
</text></th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><text><SENT sid="899" pm="."><plain>M. tbc PRAHA 131 </plain></SENT>
</text></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="900" pm="."><plain>14 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="901" pm="."><plain>21 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="902" pm="."><plain>14 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="903" pm="."><plain>21 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="904" pm="."><plain>14 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="905" pm="."><plain>21 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="906" pm="."><plain>14 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="907" pm="."><plain>21 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="908" pm="."><plain>14 days </plain></SENT>
</text></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="909" pm="."><plain>21 days </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="910" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="911" pm="."><plain>4-CH3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="912" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="913" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="914" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="915" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="916" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="917" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="918" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="919" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="920" pm="."><plain>250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="921" pm="."><plain>250 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="922" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="923" pm="."><plain>4-NH2 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="924" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="925" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="926" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="927" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="928" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="929" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="930" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="931" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="932" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="933" pm="."><plain>125 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="934" pm="."><plain>INH </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="935" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="936" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="937" pm="."><plain>62.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="938" pm="."><plain>15.63 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="939" pm="."><plain>15.63 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="940" pm="."><plain>15.63 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="941" pm="."><plain>15.63 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="942" pm="."><plain>15.63 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="943" pm="."><plain>31.25 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="944" pm="."><plain>15.63 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="945" pm="."><plain>31.25 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="946" pm="."><plain>RFM </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="947" pm="."><plain>- </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="948" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="949" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="950" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="951" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="952" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="953" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="954" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="955" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="956" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="957" pm="."><plain>&gt;15.63 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="958" pm="."><plain>MDR-TB strains: 234/2005 resistant to INH, RFM, rifabutin, streptomycin, ethambutol and ofloxacin; Praha 1 resistant to INH, RFM, rifabutin, streptomycin, ethambutol and clofazimine; 9449/2007 and Praha 4 both resistant to INH, RIF, rifabutin, ethambutol and streptomycin; XDR-TB strain: Praha 131 resistant to INH, RIF, rifabutin, streptomycin, ethambutol, ofloxacin, gentamicin and amikacin. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="molecules-22-00223-t004" position="float"><object-id pub-id-type="pii">molecules-22-00223-t004_Table 4</object-id><label>Table 4</label><caption><p><text><SENT sid="959" pm="."><plain>Cytotoxicity of active compounds and calculated selectivity index (SI) values. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="960" pm="."><plain>Compound </plain></SENT>
</text></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="961" pm="."><plain>IC50 (µM) </plain></SENT>
</text></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="962" pm="."><plain>SI (IC50/MIC) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="963" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="964" pm="."><plain>76.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="965" pm="."><plain>1.8 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="966" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="967" pm="."><plain>&gt;250 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="968" pm="."><plain>&gt;41.7 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="969" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="970" pm="."><plain>&gt;750 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="971" pm="."><plain>&gt;28.8 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="972" pm="."><plain>12 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="973" pm="."><plain>57.3 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="974" pm="."><plain>1.4 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="molecules-22-00223-t005" position="float"><object-id pub-id-type="pii">molecules-22-00223-t005_Table 5</object-id><label>Table 5</label><caption><p><text><SENT sid="975" pm="."><plain>Results of affinity calculations by Glide Scoring function in relation with in vitro activity against M. tuberculosis H37Rv. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="976" pm="."><plain>Compound </plain></SENT>
</text></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="977" pm="."><plain>Affinity (kcal/mol) </plain></SENT>
</text></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="978" pm="."><plain>MIC M. tbc H37Rv (µM) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="979" pm="."><plain>4TZK Ligand </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="980" pm="."><plain>−9.82 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="981" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="982" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="983" pm="."><plain>−8.47 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="984" pm="."><plain>42 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="985" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="986" pm="."><plain>−7.40 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="987" pm="."><plain>6 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="988" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="989" pm="."><plain>−7.82 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="990" pm="."><plain>26 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="991" pm="."><plain>12 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="992" pm="."><plain>−8.49 </plain></SENT>
</text></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><text><SENT sid="993" pm="."><plain>42 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></sec></back></article>
